CA2598208A1 - Tetrahydronaphthalene derivatives, processes for their preparation and their use as antiinflammatory agents - Google Patents
Tetrahydronaphthalene derivatives, processes for their preparation and their use as antiinflammatory agents Download PDFInfo
- Publication number
- CA2598208A1 CA2598208A1 CA002598208A CA2598208A CA2598208A1 CA 2598208 A1 CA2598208 A1 CA 2598208A1 CA 002598208 A CA002598208 A CA 002598208A CA 2598208 A CA2598208 A CA 2598208A CA 2598208 A1 CA2598208 A1 CA 2598208A1
- Authority
- CA
- Canada
- Prior art keywords
- group
- general formula
- compound
- groups
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 75
- 230000008569 process Effects 0.000 title claims description 39
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical class C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 title claims description 18
- 238000002360 preparation method Methods 0.000 title description 8
- 239000002260 anti-inflammatory agent Substances 0.000 title description 3
- 229940121363 anti-inflammatory agent Drugs 0.000 title description 3
- 238000004519 manufacturing process Methods 0.000 claims abstract description 10
- 150000001875 compounds Chemical class 0.000 claims description 151
- -1 pyrazolo[1,5-a]pyridinyl Chemical group 0.000 claims description 80
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 40
- 125000005843 halogen group Chemical group 0.000 claims description 36
- 125000001424 substituent group Chemical group 0.000 claims description 30
- 125000004432 carbon atom Chemical group C* 0.000 claims description 25
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 24
- 125000001072 heteroaryl group Chemical group 0.000 claims description 20
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims description 19
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 claims description 18
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 18
- 125000000623 heterocyclic group Chemical group 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 16
- 238000011282 treatment Methods 0.000 claims description 15
- 125000003118 aryl group Chemical group 0.000 claims description 13
- 229910052799 carbon Inorganic materials 0.000 claims description 13
- 125000000468 ketone group Chemical group 0.000 claims description 13
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 13
- 238000006243 chemical reaction Methods 0.000 claims description 12
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 9
- 230000004054 inflammatory process Effects 0.000 claims description 9
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 9
- 125000006239 protecting group Chemical group 0.000 claims description 8
- 125000002619 bicyclic group Chemical group 0.000 claims description 7
- 125000002950 monocyclic group Chemical group 0.000 claims description 7
- 125000001624 naphthyl group Chemical group 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 229920006395 saturated elastomer Polymers 0.000 claims description 7
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 6
- 150000001299 aldehydes Chemical class 0.000 claims description 6
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 125000003107 substituted aryl group Chemical group 0.000 claims description 6
- 125000004434 sulfur atom Chemical group 0.000 claims description 6
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 claims description 5
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims description 5
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 4
- 239000002841 Lewis acid Substances 0.000 claims description 4
- 125000005024 alkenyl aryl group Chemical group 0.000 claims description 4
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 4
- 125000003277 amino group Chemical group 0.000 claims description 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 4
- 125000005045 dihydroisoquinolinyl group Chemical group C1(NC=CC2=CC=CC=C12)* 0.000 claims description 4
- 150000007517 lewis acids Chemical class 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical group O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 3
- 125000005217 alkenylheteroaryl group Chemical group 0.000 claims description 3
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims description 3
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 3
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 claims description 3
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 claims description 3
- 125000001070 dihydroindolyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims description 3
- 125000004611 dihydroisoindolyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims description 3
- 125000001041 indolyl group Chemical group 0.000 claims description 3
- 125000003384 isochromanyl group Chemical group C1(OCCC2=CC=CC=C12)* 0.000 claims description 3
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 claims description 3
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 3
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 claims description 3
- 125000005633 phthalidyl group Chemical group 0.000 claims description 3
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims description 3
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 3
- 229910052717 sulfur Inorganic materials 0.000 claims description 3
- 239000011593 sulfur Substances 0.000 claims description 3
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 claims description 2
- 238000006596 Alder-ene reaction Methods 0.000 claims description 2
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 claims description 2
- 150000001728 carbonyl compounds Chemical class 0.000 claims description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 2
- 150000002466 imines Chemical class 0.000 claims description 2
- 239000012948 isocyanate Substances 0.000 claims description 2
- 150000002513 isocyanates Chemical class 0.000 claims description 2
- 150000002540 isothiocyanates Chemical class 0.000 claims description 2
- 150000007522 mineralic acids Chemical class 0.000 claims description 2
- 150000007524 organic acids Chemical class 0.000 claims description 2
- 229940127557 pharmaceutical product Drugs 0.000 claims description 2
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 claims description 2
- ZWZVWGITAAIFPS-UHFFFAOYSA-N thiophosgene Chemical compound ClC(Cl)=S ZWZVWGITAAIFPS-UHFFFAOYSA-N 0.000 claims description 2
- 230000001741 anti-phlogistic effect Effects 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 22
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 21
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 20
- 230000002757 inflammatory effect Effects 0.000 description 19
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- 208000010668 atopic eczema Diseases 0.000 description 18
- 230000000172 allergic effect Effects 0.000 description 17
- 230000002062 proliferating effect Effects 0.000 description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- 125000004122 cyclic group Chemical group 0.000 description 12
- 208000035475 disorder Diseases 0.000 description 12
- 238000003786 synthesis reaction Methods 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 11
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 10
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 10
- 125000000217 alkyl group Chemical group 0.000 description 10
- 235000019253 formic acid Nutrition 0.000 description 10
- 238000005160 1H NMR spectroscopy Methods 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 101150041968 CDC13 gene Proteins 0.000 description 8
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 8
- 102000003676 Glucocorticoid Receptors Human genes 0.000 description 7
- 108090000079 Glucocorticoid Receptors Proteins 0.000 description 7
- 230000003110 anti-inflammatory effect Effects 0.000 description 7
- 150000003254 radicals Chemical class 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000003862 glucocorticoid Substances 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 208000019693 Lung disease Diseases 0.000 description 5
- 102000016540 Tyrosine aminotransferases Human genes 0.000 description 5
- 108010042606 Tyrosine transaminase Proteins 0.000 description 5
- 239000012043 crude product Substances 0.000 description 5
- 125000000753 cycloalkyl group Chemical group 0.000 description 5
- 229910052731 fluorine Inorganic materials 0.000 description 5
- 239000012299 nitrogen atmosphere Substances 0.000 description 5
- 239000012074 organic phase Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 5
- 239000003643 water by type Substances 0.000 description 5
- 238000010626 work up procedure Methods 0.000 description 5
- 208000026872 Addison Disease Diseases 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 150000003857 carboxamides Chemical class 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 239000011737 fluorine Substances 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 229910052938 sodium sulfate Inorganic materials 0.000 description 4
- 235000011152 sodium sulphate Nutrition 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 229940037128 systemic glucocorticoids Drugs 0.000 description 4
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 3
- 206010002199 Anaphylactic shock Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 208000012659 Joint disease Diseases 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 208000025747 Rheumatic disease Diseases 0.000 description 3
- 206010039085 Rhinitis allergic Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 125000004414 alkyl thio group Chemical group 0.000 description 3
- 125000001118 alkylidene group Chemical group 0.000 description 3
- 201000010105 allergic rhinitis Diseases 0.000 description 3
- 208000003455 anaphylaxis Diseases 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 229940117173 croton oil Drugs 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- 150000002367 halogens Chemical class 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- HTKWJLCTSHNBEL-UHFFFAOYSA-N naphthalene-2-carboxamide Chemical compound C1=C(C=CC2=CC=CC=C12)C(=O)N.C1=C(C=CC2=CC=CC=C12)C(=O)N HTKWJLCTSHNBEL-UHFFFAOYSA-N 0.000 description 3
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 102000003998 progesterone receptors Human genes 0.000 description 3
- 108090000468 progesterone receptors Proteins 0.000 description 3
- 230000035939 shock Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 229940124530 sulfonamide Drugs 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 2
- DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 2
- ZSOLVRRGFFRUNE-UHFFFAOYSA-N 1-benzofuran-5-carboxamide Chemical compound NC(=O)C1=CC=C2OC=CC2=C1 ZSOLVRRGFFRUNE-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- WRAXUJRYXGHENJ-UHFFFAOYSA-N 6-fluoro-5-methoxy-4,4-dimethyl-2-(trifluoromethyl)-1,3-dihydronaphthalene-1,2-diol Chemical compound OC1C(O)(C(F)(F)F)CC(C)(C)C2=C1C=CC(F)=C2OC WRAXUJRYXGHENJ-UHFFFAOYSA-N 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 2
- 102100032187 Androgen receptor Human genes 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 206010048962 Brain oedema Diseases 0.000 description 2
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 description 2
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- 229940126083 M3 antagonist Drugs 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 150000001204 N-oxides Chemical class 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 206010037423 Pulmonary oedema Diseases 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 206010039807 Secondary adrenocortical insufficiency Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 108010080146 androgen receptors Proteins 0.000 description 2
- 125000005427 anthranyl group Chemical group 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- 208000006752 brain edema Diseases 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 230000003412 degenerative effect Effects 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 125000000723 dihydrobenzofuranyl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 description 2
- 125000005044 dihydroquinolinyl group Chemical group N1(CC=CC2=CC=CC=C12)* 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- LMOINURANNBYCM-UHFFFAOYSA-N metaproterenol Chemical compound CC(C)NCC(O)C1=CC(O)=CC(O)=C1 LMOINURANNBYCM-UHFFFAOYSA-N 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 230000000414 obstructive effect Effects 0.000 description 2
- 229960002657 orciprenaline Drugs 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 208000005333 pulmonary edema Diseases 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000002464 receptor antagonist Substances 0.000 description 2
- 229940044551 receptor antagonist Drugs 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 229960002052 salbutamol Drugs 0.000 description 2
- 201000000306 sarcoidosis Diseases 0.000 description 2
- 239000012047 saturated solution Substances 0.000 description 2
- 208000023087 secondary adrenal insufficiency Diseases 0.000 description 2
- 150000003456 sulfonamides Chemical class 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 125000000025 triisopropylsilyl group Chemical group C(C)(C)[Si](C(C)C)(C(C)C)* 0.000 description 2
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 1
- 125000006002 1,1-difluoroethyl group Chemical group 0.000 description 1
- NENLYAQPNATJSU-UHFFFAOYSA-N 1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline Chemical compound C1NCCC2CCCCC21 NENLYAQPNATJSU-UHFFFAOYSA-N 0.000 description 1
- POTIYWUALSJREP-UHFFFAOYSA-N 1,2,3,4,4a,5,6,7,8,8a-decahydroquinoline Chemical compound N1CCCC2CCCCC21 POTIYWUALSJREP-UHFFFAOYSA-N 0.000 description 1
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
- QFMZQPDHXULLKC-UHFFFAOYSA-N 1,2-bis(diphenylphosphino)ethane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCP(C=1C=CC=CC=1)C1=CC=CC=C1 QFMZQPDHXULLKC-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- QHKJIJXBJCOABP-UHFFFAOYSA-N 1-benzofuran-2-carboxamide Chemical compound C1=CC=C2OC(C(=O)N)=CC2=C1 QHKJIJXBJCOABP-UHFFFAOYSA-N 0.000 description 1
- APBBTKKLSNPFDP-UHFFFAOYSA-N 1-methyl-1,2,3,4-tetrahydronaphthalene Chemical compound C1=CC=C2C(C)CCCC2=C1 APBBTKKLSNPFDP-UHFFFAOYSA-N 0.000 description 1
- VSWPGAIWKHPTKX-UHFFFAOYSA-N 1-methyl-10-[2-(4-methyl-1-piperazinyl)-1-oxoethyl]-5H-thieno[3,4-b][1,5]benzodiazepin-4-one Chemical compound C1CN(C)CCN1CC(=O)N1C2=CC=CC=C2NC(=O)C2=CSC(C)=C21 VSWPGAIWKHPTKX-UHFFFAOYSA-N 0.000 description 1
- XHLHPRDBBAGVEG-UHFFFAOYSA-N 1-tetralone Chemical compound C1=CC=C2C(=O)CCCC2=C1 XHLHPRDBBAGVEG-UHFFFAOYSA-N 0.000 description 1
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- 125000001698 2H-pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- JZIBVTUXIVIFGC-UHFFFAOYSA-N 2H-pyrrole Chemical compound C1C=CC=N1 JZIBVTUXIVIFGC-UHFFFAOYSA-N 0.000 description 1
- QMDFJHAAWUGVKQ-UHFFFAOYSA-N 2h-thiopyran Chemical compound C1SC=CC=C1 QMDFJHAAWUGVKQ-UHFFFAOYSA-N 0.000 description 1
- KCKZIWSINLBROE-UHFFFAOYSA-N 3,4-dihydro-1h-naphthalen-2-one Chemical compound C1=CC=C2CC(=O)CCC2=C1 KCKZIWSINLBROE-UHFFFAOYSA-N 0.000 description 1
- 125000001331 3-methylbutoxy group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000004715 3-methylbutylthio group Chemical group CC(CCS*)C 0.000 description 1
- LGRQUXHYJBFGTM-UHFFFAOYSA-N 4H-imidazole Chemical compound C1C=NC=N1 LGRQUXHYJBFGTM-UHFFFAOYSA-N 0.000 description 1
- MRUWJENAYHTDQG-UHFFFAOYSA-N 4H-pyran Chemical compound C1C=COC=C1 MRUWJENAYHTDQG-UHFFFAOYSA-N 0.000 description 1
- 125000001826 4H-pyranyl group Chemical group O1C(=CCC=C1)* 0.000 description 1
- NILYRCYRBPDITI-UHFFFAOYSA-N 4H-pyrazole Chemical compound C1C=NN=C1 NILYRCYRBPDITI-UHFFFAOYSA-N 0.000 description 1
- STBGWNRZMPCVTG-UHFFFAOYSA-N 4h-thiopyran Chemical compound C1C=CSC=C1 STBGWNRZMPCVTG-UHFFFAOYSA-N 0.000 description 1
- OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 1
- GOJWUHZAOKJJRC-UHFFFAOYSA-N 6-fluoro-5-methoxy-4,4-dimethyl-1-(pyrazolo[1,5-a]pyridin-3-ylmethylamino)-2-(trifluoromethyl)-1,3-dihydronaphthalen-2-ol Chemical compound C1=NN2C=CC=CC2=C1CNC1C(C=CC(F)=C2OC)=C2C(C)(C)CC1(O)C(F)(F)F GOJWUHZAOKJJRC-UHFFFAOYSA-N 0.000 description 1
- HYYTYZKXZSTGGS-UHFFFAOYSA-N 7-methoxy-4,4-dimethyl-2-(trifluoromethyl)-1,3-dihydronaphthalene-1,2-diol Chemical compound OC1C(O)(C(F)(F)F)CC(C)(C)C=2C1=CC(OC)=CC=2 HYYTYZKXZSTGGS-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000005676 Adrenogenital syndrome Diseases 0.000 description 1
- 206010057380 Allergic keratitis Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 206010001889 Alveolitis Diseases 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 208000028185 Angioedema Diseases 0.000 description 1
- 206010003267 Arthritis reactive Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 101100244150 Bos taurus PLCZ1 gene Proteins 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 description 1
- 102000004500 CCR1 Receptors Human genes 0.000 description 1
- 108010017319 CCR1 Receptors Proteins 0.000 description 1
- LERNTVKEWCAPOY-VOGVJGKGSA-N C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 Chemical compound C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 LERNTVKEWCAPOY-VOGVJGKGSA-N 0.000 description 1
- 102000009410 Chemokine receptor Human genes 0.000 description 1
- 108050000299 Chemokine receptor Proteins 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010012441 Dermatitis bullous Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- 206010013457 Dissociation Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 206010015218 Erythema multiforme Diseases 0.000 description 1
- 206010015226 Erythema nodosum Diseases 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- 241001516614 Exema Species 0.000 description 1
- 208000028387 Felty syndrome Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 208000007465 Giant cell arteritis Diseases 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 101000988419 Homo sapiens cAMP-specific 3',5'-cyclic phosphodiesterase 4D Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
- 206010021750 Infantile Spasms Diseases 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- UQOFGTXDASPNLL-XHNCKOQMSA-N Muscarine Chemical compound C[C@@H]1O[C@H](C[N+](C)(C)C)C[C@H]1O UQOFGTXDASPNLL-XHNCKOQMSA-N 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 208000022873 Ocular disease Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000003435 Optic Neuritis Diseases 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 201000011152 Pemphigus Diseases 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 description 1
- VQDBNKDJNJQRDG-UHFFFAOYSA-N Pirbuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=N1 VQDBNKDJNJQRDG-UHFFFAOYSA-N 0.000 description 1
- 208000007048 Polymyalgia Rheumatica Diseases 0.000 description 1
- 206010052381 Primary adrenal insufficiency Diseases 0.000 description 1
- 206010036774 Proctitis Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 1
- 241001303601 Rosacea Species 0.000 description 1
- 101100311330 Schizosaccharomyces pombe (strain 972 / ATCC 24843) uap56 gene Proteins 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 208000016247 Soft tissue disease Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 101100244155 Sus scrofa PLCZ gene Proteins 0.000 description 1
- 206010042742 Sympathetic ophthalmia Diseases 0.000 description 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 201000002015 Thyroid Crisis Diseases 0.000 description 1
- 206010043786 Thyrotoxic crisis Diseases 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 206010047112 Vasculitides Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 201000006791 West syndrome Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 231100000354 acute hepatitis Toxicity 0.000 description 1
- 239000000048 adrenergic agonist Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 125000005025 alkynylaryl group Chemical group 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- PECIYKGSSMCNHN-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=NC=N[C]21.O=C1N(C)C(=O)N(C)C2=NC=N[C]21 PECIYKGSSMCNHN-UHFFFAOYSA-N 0.000 description 1
- 229960003556 aminophylline Drugs 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
- 125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 208000002479 balanitis Diseases 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229960000585 bitolterol mesylate Drugs 0.000 description 1
- HODFCFXCOMKRCG-UHFFFAOYSA-N bitolterol mesylate Chemical compound CS([O-])(=O)=O.C1=CC(C)=CC=C1C(=O)OC1=CC=C(C(O)C[NH2+]C(C)(C)C)C=C1OC(=O)C1=CC=C(C)C=C1 HODFCFXCOMKRCG-UHFFFAOYSA-N 0.000 description 1
- 208000010217 blepharitis Diseases 0.000 description 1
- 239000003914 blood derivative Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
- YSHOWEKUVWPFNR-UHFFFAOYSA-N burgess reagent Chemical compound CC[N+](CC)(CC)S(=O)(=O)N=C([O-])OC YSHOWEKUVWPFNR-UHFFFAOYSA-N 0.000 description 1
- 102100029170 cAMP-specific 3',5'-cyclic phosphodiesterase 4D Human genes 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- AOGYCOYQMAVAFD-UHFFFAOYSA-N chlorocarbonic acid Chemical compound OC(Cl)=O AOGYCOYQMAVAFD-UHFFFAOYSA-N 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 125000000332 coumarinyl group Chemical group O1C(=O)C(=CC2=CC=CC=C12)* 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000006352 cycloaddition reaction Methods 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 238000005888 cyclopropanation reaction Methods 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 125000004652 decahydroisoquinolinyl group Chemical group C1(NCCC2CCCCC12)* 0.000 description 1
- 125000004856 decahydroquinolinyl group Chemical group N1(CCCC2CCCCC12)* 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- MHDVGSVTJDSBDK-UHFFFAOYSA-N dibenzyl ether Chemical class C=1C=CC=CC=1COCC1=CC=CC=C1 MHDVGSVTJDSBDK-UHFFFAOYSA-N 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 208000018459 dissociative disease Diseases 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000010410 dusting Methods 0.000 description 1
- 210000000613 ear canal Anatomy 0.000 description 1
- 210000000959 ear middle Anatomy 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 125000005448 ethoxyethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- 125000004705 ethylthio group Chemical group C(C)S* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 125000003784 fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 229960002848 formoterol Drugs 0.000 description 1
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- JKFAIQOWCVVSKC-UHFFFAOYSA-N furazan Chemical compound C=1C=NON=1 JKFAIQOWCVVSKC-UHFFFAOYSA-N 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 238000005647 hydrohalogenation reaction Methods 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 229960004078 indacaterol Drugs 0.000 description 1
- QZZUEBNBZAPZLX-QFIPXVFZSA-N indacaterol Chemical compound N1C(=O)C=CC2=C1C(O)=CC=C2[C@@H](O)CNC1CC(C=C(C(=C2)CC)CC)=C2C1 QZZUEBNBZAPZLX-QFIPXVFZSA-N 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 229960001361 ipratropium bromide Drugs 0.000 description 1
- KEWHKYJURDBRMN-ZEODDXGYSA-M ipratropium bromide hydrate Chemical compound O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-ZEODDXGYSA-M 0.000 description 1
- 201000004614 iritis Diseases 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- 125000003151 isocoumarinyl group Chemical group C1(=O)OC(=CC2=CC=CC=C12)* 0.000 description 1
- 125000000493 isoindolonyl group Chemical group C1(N=C(C2=CC=CC=C12)*)=O 0.000 description 1
- 229960001317 isoprenaline Drugs 0.000 description 1
- 229940039009 isoproterenol Drugs 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- CFHGBZLNZZVTAY-UHFFFAOYSA-N lawesson's reagent Chemical compound C1=CC(OC)=CC=C1P1(=S)SP(=S)(C=2C=CC(OC)=CC=2)S1 CFHGBZLNZZVTAY-UHFFFAOYSA-N 0.000 description 1
- 231100000832 liver cell necrosis Toxicity 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- 125000006431 methyl cyclopropyl group Chemical group 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 239000002395 mineralocorticoid Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- FVSUYFWWFUVGRG-UHFFFAOYSA-N naphthalen-1-ylurea Chemical compound C1=CC=C2C(NC(=O)N)=CC=CC2=C1 FVSUYFWWFUVGRG-UHFFFAOYSA-N 0.000 description 1
- XNLBCXGRQWUJLU-UHFFFAOYSA-N naphthalene-2-carbonyl chloride Chemical compound C1=CC=CC2=CC(C(=O)Cl)=CC=C21 XNLBCXGRQWUJLU-UHFFFAOYSA-N 0.000 description 1
- SWBLLSQMOMPTMC-UHFFFAOYSA-N naphthalene-2-sulfonamide Chemical compound C1=CC=CC2=CC(S(=O)(=O)N)=CC=C21 SWBLLSQMOMPTMC-UHFFFAOYSA-N 0.000 description 1
- UFWIBTONFRDIAS-UHFFFAOYSA-N naphthalene-acid Natural products C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 1
- 150000002790 naphthalenes Chemical class 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 230000003448 neutrophilic effect Effects 0.000 description 1
- 208000028931 non-acquired combined pituitary hormone deficiency Diseases 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 206010033072 otitis externa Diseases 0.000 description 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
- 229960001609 oxitropium bromide Drugs 0.000 description 1
- LCELQERNWLBPSY-KHSTUMNDSA-M oxitropium bromide Chemical compound [Br-].C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3[N+]([C@H](C2)[C@@H]2[C@H]3O2)(C)CC)=CC=CC=C1 LCELQERNWLBPSY-KHSTUMNDSA-M 0.000 description 1
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 1
- 210000003695 paranasal sinus Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 201000001976 pemphigus vulgaris Diseases 0.000 description 1
- 208000000689 peptic esophagitis Diseases 0.000 description 1
- 125000005010 perfluoroalkyl group Chemical group 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 1
- CYQAYERJWZKYML-UHFFFAOYSA-N phosphorus pentasulfide Chemical compound S1P(S2)(=S)SP3(=S)SP1(=S)SP2(=S)S3 CYQAYERJWZKYML-UHFFFAOYSA-N 0.000 description 1
- 238000005375 photometry Methods 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- 229960005414 pirbuterol Drugs 0.000 description 1
- 229960004633 pirenzepine Drugs 0.000 description 1
- RMHMFHUVIITRHF-UHFFFAOYSA-N pirenzepine Chemical compound C1CN(C)CCN1CC(=O)N1C2=NC=CC=C2NC(=O)C2=CC=CC=C21 RMHMFHUVIITRHF-UHFFFAOYSA-N 0.000 description 1
- 206010035116 pityriasis rubra pilaris Diseases 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-M pivalate Chemical compound CC(C)(C)C([O-])=O IUGYQRQAERSCNH-UHFFFAOYSA-M 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- 201000006292 polyarteritis nodosa Diseases 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 230000018656 positive regulation of gluconeogenesis Effects 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 description 1
- KBJMYBSEFSJJNV-UHFFFAOYSA-N pyrazolo[1,5-a]pyridine-3-carbaldehyde Chemical compound C1=CC=CC2=C(C=O)C=NN21 KBJMYBSEFSJJNV-UHFFFAOYSA-N 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- PPPQPLAZICCCNM-UHFFFAOYSA-N quinoxaline-6-carboxamide Chemical compound N1=CC=NC2=CC(C(=O)N)=CC=C21 PPPQPLAZICCCNM-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 208000002574 reactive arthritis Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 201000004700 rosacea Diseases 0.000 description 1
- 229960004017 salmeterol Drugs 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000003369 serotonin 5-HT3 receptor antagonist Substances 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 125000003808 silyl group Chemical class [H][Si]([H])([H])[*] 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 102000005969 steroid hormone receptors Human genes 0.000 description 1
- 108020003113 steroid hormone receptors Proteins 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 101150018444 sub2 gene Proteins 0.000 description 1
- 201000007497 subacute thyroiditis Diseases 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 150000003455 sulfinic acids Chemical class 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229950004351 telenzepine Drugs 0.000 description 1
- 206010043207 temporal arteritis Diseases 0.000 description 1
- 229960000195 terbutaline Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical compound C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 1
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000006337 tetrafluoro ethyl group Chemical group 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000005942 tetrahydropyridyl group Chemical group 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000005329 tetralinyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 229960000257 tiotropium bromide Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- JMXKSZRRTHPKDL-UHFFFAOYSA-N titanium ethoxide Chemical compound [Ti+4].CC[O-].CC[O-].CC[O-].CC[O-] JMXKSZRRTHPKDL-UHFFFAOYSA-N 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 125000002827 triflate group Chemical group FC(S(=O)(=O)O*)(F)F 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 208000002003 vulvitis Diseases 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C217/74—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/67—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/74—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/20—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Otolaryngology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
The invention relates to poly-substituted tetrahydronaphtalene derivatives of formula (I) and to a method for the production and the use thereof in the form of antiphlogistics.
Description
Tetrahydronaphthalene derivatives, processes for their preparation and their use as antiinflammatory agents Introduction The invention relates to tetrahydronaphthalene derivatives, processes for their preparation and their use as antiinflammatory agents.
Open-chain non-steroidal antiinflammatory agents are known in the art (DE 100 38 639 and WO 02/10143). These compounds show experimentally dissociations between antiinflammatory and unwanted metabolic effects and are superior to non-steroidal glucocorticoids described to date or exhibit at least as good an effect.
The present invention provides further non-steroidal antiinflammatory agents.
Brief description of the invention The present invention relates to compounds of the general formula (I) RB R' R' ~
RZ Rs R" R'2 HN~
X
R
in which R 1 and R2 are independently of one another a hydrogen atom, a hydroxy group, a halogen atom, an optionally substituted (C1-C10)-alkyl group, a (C1-Clo) -alkoxy group, a (C1-Clo) -alkylthio group, a (C1-CS)-perfluoroalkyl group, a cyano group, a nitro group, or an -NR9R9a group, or R' and R 2 together form a group selected from the groups -0- (CH2) n-0-, -0- (CH2) n-CH2-, -O-CH=CH-, - (CH2) n+2-r -NH- (CH2) n+i-, -N (C1-C3-alkyl) - (CH2) n+i-and -NH-N=CH-, where n is 1 or 2, and the terminal oxygen atoms and/or carbon atoms and/or nitrogen atoms are linked to directly adjacent ring carbon atoms, R11 is a hydrogen atom, a hydroxy group, a halogen atom, a cyano group, an optionally substituted (C1-Clo) -alkyl group, a (C1-Clo) -alkoxy group, a (C1-Clo) -alkylthio group, or a (C1-C5) -perfluoroalkyl group, R12 is a hydrogen atom, a hydroxy group, a halogen atom, a cyano group, an optionally substituted (CI-Clo) -alkyl group, or a (C1-Clo) -alkoxy group, R3 is a C1-Clo-alkyl group which is optionally substituted by 1 to 3 hydroxy groups, 1 to 3 halogen atoms, and/or 1 to 3(C1-CS)-alkoxy groups, an optionally substituted (C3-C7) -cycloalkyl group, an optionally substituted heterocyclyl group, an optionally substituted aryl group, or a mono- or bicyclic heteroaryl group which is optionally substituted by one or more groups which are selected independently of one another from (C1-C5)-alkyl groups which themselves may optionally be substituted by 1 to 3 hydroxy or 1 to 3-C00R13 groups, (C1-C5) -alkoxy groups, halogen atoms, hydroxy groups, -NRgR9a groups, and exo methylene groups and optionally comprises 1 to 4 nitrogen atoms and/or 1 to 2 oxygen atoms and/or 1 to 2 sulfur atoms and/or 1 to 2 keto groups, this group being linked by any position to the group X and possibly being optionally hydrogenated at one or more positions, R4 is a hydroxy group, an -OR10 group or an -0 (CO) Rl0 group, R5 is a (Cl-C1 ) -alkyl group which is optionally partly or completely fluorinated, a (C3-C7) cycloalkyl group, a (C1-C8) alkyl-(C3-C7) cycloalkyl group, a (C2-C$) alkenyl-(C3-C7) cycloalkyl group, a heterocyclyl group, a (C1-C$) alkylheterocyclyl group, a (C2-CB) -alkenylheterocyclyl group, an aryl group, a (C1-C$) alkylaryl group, a(C2-C8) alkenylaryl group, a (CZ-C8) -alkynylaryl group, a mono- or bicyclic heteroaryl group which is optionally substituted by 1 to 2 keto groups, 1 to 2 (C1-C5) -alkyl groups, 1 to 2 (C1-C5) -alkoxy groups, 1 to 3 halogen atoms, and/or 1 to 2 exo methylene groups and comprises 1 to 3 nitrogen atoms and/or 1 to 2 oxygen atoms and/or 1 to 2 sulfur atoms, a (C1-C8) alkylheteroaryl group, a (CZ-C8) alkenylheteroaryl group, or a (Cz-C8)alkynylheteroaryl group, this group being linked by any position to the tetrahydronaphthalene system and possibly being optionally hydrogenated at one or more positions, R6 is a hydrogen atom, a halogen atom, or an optionally substituted (C1-C10)alkyl group, R7 and R8 are independently of one another a hydrogen atom, a halogen atom, an optionally substituted (C1-C10) -alkyl group, a cyano group, together a (Ci-Cio) -alkylidene group or together with the carbon atom of the tetrahydronaphthalene system an optionally substituted (C3-C6) -cyclalkyl ring;
or R6 and R7 together form a fused five- to eight-membered saturated or unsaturated carbocycle or heterocycle which is optionally substituted by 1 to 2 keto groups, 1 to 2 (C1-C5) -alkyl groups, 1 to 2 (C1-C5)-alkoxy groups, and/or 1 to 4 halogen atoms;
or R1 and R8 together form a fused five- to eight-membered saturated or unsaturated carbocycle or heterocycle which is optionally substituted by 1 to 2 keto groups, 1 to 2 (C1-C5) -alkyl groups, 1 to 2 (C1-C5)-alkoxy groups, and/or 1 to 4 halogen atoms;
R9 and R9a are independently of one another a hydrogen atom, (C1-C5) -alkyl or - (CO) - (C1-C5) -alkyl, R10 is a(C1-C10) -alkyl group or any hydroxy protective group, R13 is a hydrogen atom or a(C1-C5) -alkyl group, and X is a group -C(=O)-, -C(=S)-, -C(=O)-NH-, -C (=S) -NH-, -S ( O ) m (where m = 1 or 2 ) , -C (=0) -0-, -C (=S) -0- or a group -(CHZ) P- (where p = 1, 2 or 3), where if X comprises a carbonyl or thiocarbonyl function, this function is linked to the group -NH- in the general formula (I), with the proviso that if R3 is an optionally substituted (C1-C10) -alkyl group, X cannot be a - ( CH2 ) p- group;
in the form of any stereoisomer or of a mixture of stereoisomers; or as pharmacologically acceptable salt or derivative.
The present invention further relates to processes for preparing compounds of the general formula (I) as described herein.
The present invention further relates to pharmaceutical compositions which include one or more compounds of the general formula (I) in combination with one or more pharmaceutical carriers or excipients.
The present invention additionally relates to the use of the compounds of the general formula (I) for manufacturing pharmaceutical compositions having an antiinflammatory effect.
-The present invention further relates to compounds of the general formula (IV) Ra R' R' ~
R2 Re R" R72 NHZ (IV) in which the substituents R1 to RlZ have the abovementioned meanings, and to the use of these compounds for preparing compounds of the general formula (I) as described above.
Detailed description of the invention Definitions The term halogen atom or halogen means a fluorine, chlorine, bromine or iodine atom. A fluorine, chlorine or bromine atom is preferred.
The alkyl groups mentioned in the definitions of the general formula (I) may be straight-chain or branched and are for example a methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl or n-pentyl, 2,2-dimethylpropyl, 2-methylbutyl or 3-methylbutyl group, and the hexyl, heptyl, nonyl, decyl group and derivatives thereof branched in any way. Alkyl groups which comprise 1 to 10, 1 to 8 or 1 to 5 carbon atoms are preferred. A methyl or ethyl group is particularly preferred.
The abovementioned alkyl groups may optionally be substituted by 1 to 5, preferably 1 to 3, groups which are selected independently of one another from hydroxy, cyano, nitro, -COOR13, (C1-C5) -alkoxy groups, halogen atoms, -NR9R9a, a partly or completely fluorinated (C1-C3) -alkyl group. The alkyl groups may preferably be substituted by 1 to 3 halogen atoms and/or 1 to 3 hydroxy and/or 1 to 3 cyano and/or 1 to 3-COOR13 groups. Fluorine atom, hydroxy, methoxy and/or cyano groups represent a particularly preferred subgroup of substituents.
1 to 3 hydroxy and/or 1 to 3-COOR13 groups are a further particularly preferred group of substituents for the alkyl groups. Hydroxy groups are particularly preferred in this connection.
Examples of a suitable partly or completely fluorinated alkyl group are the following partly or completely fluorinated following groups: fluoromethyl, difluoromethyl, trifluoromethyl, fluoroethyl, 1,1-difluoroethyl, 1,2-difluoroethyl, 1,1,1-trifluoro-ethyl, tetrafluoroethyl, pentafluoroethyl. Of these, the trifluoromethyl or the pentafluoroethyl are preferred. The completely fluorinated group is also called perfluoroalkyl group. The reagents which are optionally employed during the synthesis can be purchased, or the published syntheses of the corresponding reagents belong to the prior art, or published syntheses can be applied analogously.
The alkenyl groups have at least one C=C double bond and may be straight-chain or branched. Alkenyl groups having 2 to 8 carbon atoms are preferred.
The alkynyl groups have at least one C=C triple bond and may be straight-chain or branched. Alkynyl groups having 2 to 8 carbon atoms are preferred.
The alkoxy groups mentioned in the definitions of the general formula (I) may be straight-chain or branched and be for example a methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, tert-butoxy or n-pentoxy, 2,2-dimethylpropoxy, 2-methylbutoxy or 3-methylbutoxy group. C1-C5- and C1-C3-, C1-C$-, and Cl-Clo-alkoxy groups are preferred. A methoxy or ethoxy group is particularly preferred.
The alkylthio groups mentioned in the definitions of the general formula (I) may be straight-chain or branched and are for example a methylthio, ethylthio, n-propylthio, isopropylthio, n-butylthio, isobutylthio, tert-butylthio or n-pentylthio, 2,2-dimethylpropylthio, 2-methylbutylthio or 3-methylbutylthio group.
C1-C5-Alkylthio groups are preferred. A methylthio or ethylthio group is particularly preferred.
The alkoxy and alkylthio groups described above may have on their alkyl groups the same substituents which have been described hereinbefore for the alkyl groups in general. Preferred substituents for alkoxy and alkylthio groups are selected independently of one another from halogen atoms (especially fluorine and/or chlorine), hydroxy and cyano groups.
The substituent -NR9R9a means for example -NH2, -NH (CH3) , -N ( CH3 ) 2, -NH ( C2H5 ) , -N ( C2H5 ) 2, -NH (C3H-7) ~ -N (C3H7) 2, -NH (C4H9) , -N (C4H9) 2, -NH (C5H11) , -N (C5H11) 2, -NH (CO) CH3r NH ( CO ) C2H5, -NH ( CO ) C3H7, -NH ( CO ) C4H9r -NH ( CO ) C5H11.
The cycloalkyl group means a saturated cyclic group which is optionally substituted by one or more groups selected from hydroxy groups, halogen atoms, (C1-C5)-alkyl groups, (C1-C5) -alkoxy groups, -NR9R9a groups, -COOR13 groups, -CHO, cyano and has 3 to 7 ring carbon atoms such as, for example, cyclopropyl, methyl-cyclopropyl, cyclobutyl, methylcyclobutyl, cyclopentyl, methylcyclopentyl, cyclohexyl, methylcyclohexyl, cycloheptyl, methylcycloheptyl.
A (C1-C$) alkyl- (C3-C7) cycloalkyl group R5 means a cycloalkyl group (as defined above) which is linked via a straight-chain or branched (C1-C$)-alkyl unit (as defined above) to the ring system. Examples of such groups are - (CH2) -cycloalkyl, - (C2H4) -cycloalkyl, - (C3H6) -cycloalkyl, - (C4H8) -cycloalkyl, - (C5H10-cyclo-alkyl, where cycloalkyl is defined as described above.
A (C2-C8) alkenyl- (C3-C7) cycloalkyl group R5 means a cycloalkyl group (as defined above) which is linked via a straight-chain or branched (CZ-C8)-alkenyl unit to the ring system. Examples of such groups are -(CH=CH)-cycloalkyl, - [C (CH3) =CH] -cycloalkyl, -[CH=C(CH3)]-cycloalkyl, -(CH=CH-CH2)-cycloalkyl, -(CH2-CH=CH)-cycloalkyl, - (CH=CH-CH2-CH2) -cycloalkyl, - (CHZ-CH=CH-CH2) -cycloalkyl, - (CH2-CH2-CH=CH) -cycloalkyl, - (C (CH3) =CH-CHZ) -cycloalkyl, - (CH=C (CH3) -CH2) -cyclo-alkyl.
An alkylidene or exo alkylidene group means a group having 1 to 10 carbon atoms which is bonded via an exo double bond to the system (ring or chain) . (C1-C5) - and (C1-C3)-alkylidene is preferred, and exo methylene is particularly preferred.
The heterocyclyl group is a cyclic, non-aromatic group comprising one or more heteroatoms and may be for example pyrrolidine, imidazolidine, pyrazolidine, piperidine. Perhydroquinoline and perhydroisoquinoline are also included in the heterocyclyl groups of the invention.
Examples of suitable substituents for heterocyclyl and heteroaryl groups are substituents from the following group: optionally substituted C1-C5-alkyl groups, hydroxy, (C1-C5) -alkoxy, -NR9R9a, halogen, cyano, -C00R13, -CHO. The substituents may optionally also be bonded to the nitrogen atom of the heterocyclyl or heteroaryl group; N-oxides are also included in the definition.
Open-chain non-steroidal antiinflammatory agents are known in the art (DE 100 38 639 and WO 02/10143). These compounds show experimentally dissociations between antiinflammatory and unwanted metabolic effects and are superior to non-steroidal glucocorticoids described to date or exhibit at least as good an effect.
The present invention provides further non-steroidal antiinflammatory agents.
Brief description of the invention The present invention relates to compounds of the general formula (I) RB R' R' ~
RZ Rs R" R'2 HN~
X
R
in which R 1 and R2 are independently of one another a hydrogen atom, a hydroxy group, a halogen atom, an optionally substituted (C1-C10)-alkyl group, a (C1-Clo) -alkoxy group, a (C1-Clo) -alkylthio group, a (C1-CS)-perfluoroalkyl group, a cyano group, a nitro group, or an -NR9R9a group, or R' and R 2 together form a group selected from the groups -0- (CH2) n-0-, -0- (CH2) n-CH2-, -O-CH=CH-, - (CH2) n+2-r -NH- (CH2) n+i-, -N (C1-C3-alkyl) - (CH2) n+i-and -NH-N=CH-, where n is 1 or 2, and the terminal oxygen atoms and/or carbon atoms and/or nitrogen atoms are linked to directly adjacent ring carbon atoms, R11 is a hydrogen atom, a hydroxy group, a halogen atom, a cyano group, an optionally substituted (C1-Clo) -alkyl group, a (C1-Clo) -alkoxy group, a (C1-Clo) -alkylthio group, or a (C1-C5) -perfluoroalkyl group, R12 is a hydrogen atom, a hydroxy group, a halogen atom, a cyano group, an optionally substituted (CI-Clo) -alkyl group, or a (C1-Clo) -alkoxy group, R3 is a C1-Clo-alkyl group which is optionally substituted by 1 to 3 hydroxy groups, 1 to 3 halogen atoms, and/or 1 to 3(C1-CS)-alkoxy groups, an optionally substituted (C3-C7) -cycloalkyl group, an optionally substituted heterocyclyl group, an optionally substituted aryl group, or a mono- or bicyclic heteroaryl group which is optionally substituted by one or more groups which are selected independently of one another from (C1-C5)-alkyl groups which themselves may optionally be substituted by 1 to 3 hydroxy or 1 to 3-C00R13 groups, (C1-C5) -alkoxy groups, halogen atoms, hydroxy groups, -NRgR9a groups, and exo methylene groups and optionally comprises 1 to 4 nitrogen atoms and/or 1 to 2 oxygen atoms and/or 1 to 2 sulfur atoms and/or 1 to 2 keto groups, this group being linked by any position to the group X and possibly being optionally hydrogenated at one or more positions, R4 is a hydroxy group, an -OR10 group or an -0 (CO) Rl0 group, R5 is a (Cl-C1 ) -alkyl group which is optionally partly or completely fluorinated, a (C3-C7) cycloalkyl group, a (C1-C8) alkyl-(C3-C7) cycloalkyl group, a (C2-C$) alkenyl-(C3-C7) cycloalkyl group, a heterocyclyl group, a (C1-C$) alkylheterocyclyl group, a (C2-CB) -alkenylheterocyclyl group, an aryl group, a (C1-C$) alkylaryl group, a(C2-C8) alkenylaryl group, a (CZ-C8) -alkynylaryl group, a mono- or bicyclic heteroaryl group which is optionally substituted by 1 to 2 keto groups, 1 to 2 (C1-C5) -alkyl groups, 1 to 2 (C1-C5) -alkoxy groups, 1 to 3 halogen atoms, and/or 1 to 2 exo methylene groups and comprises 1 to 3 nitrogen atoms and/or 1 to 2 oxygen atoms and/or 1 to 2 sulfur atoms, a (C1-C8) alkylheteroaryl group, a (CZ-C8) alkenylheteroaryl group, or a (Cz-C8)alkynylheteroaryl group, this group being linked by any position to the tetrahydronaphthalene system and possibly being optionally hydrogenated at one or more positions, R6 is a hydrogen atom, a halogen atom, or an optionally substituted (C1-C10)alkyl group, R7 and R8 are independently of one another a hydrogen atom, a halogen atom, an optionally substituted (C1-C10) -alkyl group, a cyano group, together a (Ci-Cio) -alkylidene group or together with the carbon atom of the tetrahydronaphthalene system an optionally substituted (C3-C6) -cyclalkyl ring;
or R6 and R7 together form a fused five- to eight-membered saturated or unsaturated carbocycle or heterocycle which is optionally substituted by 1 to 2 keto groups, 1 to 2 (C1-C5) -alkyl groups, 1 to 2 (C1-C5)-alkoxy groups, and/or 1 to 4 halogen atoms;
or R1 and R8 together form a fused five- to eight-membered saturated or unsaturated carbocycle or heterocycle which is optionally substituted by 1 to 2 keto groups, 1 to 2 (C1-C5) -alkyl groups, 1 to 2 (C1-C5)-alkoxy groups, and/or 1 to 4 halogen atoms;
R9 and R9a are independently of one another a hydrogen atom, (C1-C5) -alkyl or - (CO) - (C1-C5) -alkyl, R10 is a(C1-C10) -alkyl group or any hydroxy protective group, R13 is a hydrogen atom or a(C1-C5) -alkyl group, and X is a group -C(=O)-, -C(=S)-, -C(=O)-NH-, -C (=S) -NH-, -S ( O ) m (where m = 1 or 2 ) , -C (=0) -0-, -C (=S) -0- or a group -(CHZ) P- (where p = 1, 2 or 3), where if X comprises a carbonyl or thiocarbonyl function, this function is linked to the group -NH- in the general formula (I), with the proviso that if R3 is an optionally substituted (C1-C10) -alkyl group, X cannot be a - ( CH2 ) p- group;
in the form of any stereoisomer or of a mixture of stereoisomers; or as pharmacologically acceptable salt or derivative.
The present invention further relates to processes for preparing compounds of the general formula (I) as described herein.
The present invention further relates to pharmaceutical compositions which include one or more compounds of the general formula (I) in combination with one or more pharmaceutical carriers or excipients.
The present invention additionally relates to the use of the compounds of the general formula (I) for manufacturing pharmaceutical compositions having an antiinflammatory effect.
-The present invention further relates to compounds of the general formula (IV) Ra R' R' ~
R2 Re R" R72 NHZ (IV) in which the substituents R1 to RlZ have the abovementioned meanings, and to the use of these compounds for preparing compounds of the general formula (I) as described above.
Detailed description of the invention Definitions The term halogen atom or halogen means a fluorine, chlorine, bromine or iodine atom. A fluorine, chlorine or bromine atom is preferred.
The alkyl groups mentioned in the definitions of the general formula (I) may be straight-chain or branched and are for example a methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl or n-pentyl, 2,2-dimethylpropyl, 2-methylbutyl or 3-methylbutyl group, and the hexyl, heptyl, nonyl, decyl group and derivatives thereof branched in any way. Alkyl groups which comprise 1 to 10, 1 to 8 or 1 to 5 carbon atoms are preferred. A methyl or ethyl group is particularly preferred.
The abovementioned alkyl groups may optionally be substituted by 1 to 5, preferably 1 to 3, groups which are selected independently of one another from hydroxy, cyano, nitro, -COOR13, (C1-C5) -alkoxy groups, halogen atoms, -NR9R9a, a partly or completely fluorinated (C1-C3) -alkyl group. The alkyl groups may preferably be substituted by 1 to 3 halogen atoms and/or 1 to 3 hydroxy and/or 1 to 3 cyano and/or 1 to 3-COOR13 groups. Fluorine atom, hydroxy, methoxy and/or cyano groups represent a particularly preferred subgroup of substituents.
1 to 3 hydroxy and/or 1 to 3-COOR13 groups are a further particularly preferred group of substituents for the alkyl groups. Hydroxy groups are particularly preferred in this connection.
Examples of a suitable partly or completely fluorinated alkyl group are the following partly or completely fluorinated following groups: fluoromethyl, difluoromethyl, trifluoromethyl, fluoroethyl, 1,1-difluoroethyl, 1,2-difluoroethyl, 1,1,1-trifluoro-ethyl, tetrafluoroethyl, pentafluoroethyl. Of these, the trifluoromethyl or the pentafluoroethyl are preferred. The completely fluorinated group is also called perfluoroalkyl group. The reagents which are optionally employed during the synthesis can be purchased, or the published syntheses of the corresponding reagents belong to the prior art, or published syntheses can be applied analogously.
The alkenyl groups have at least one C=C double bond and may be straight-chain or branched. Alkenyl groups having 2 to 8 carbon atoms are preferred.
The alkynyl groups have at least one C=C triple bond and may be straight-chain or branched. Alkynyl groups having 2 to 8 carbon atoms are preferred.
The alkoxy groups mentioned in the definitions of the general formula (I) may be straight-chain or branched and be for example a methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, tert-butoxy or n-pentoxy, 2,2-dimethylpropoxy, 2-methylbutoxy or 3-methylbutoxy group. C1-C5- and C1-C3-, C1-C$-, and Cl-Clo-alkoxy groups are preferred. A methoxy or ethoxy group is particularly preferred.
The alkylthio groups mentioned in the definitions of the general formula (I) may be straight-chain or branched and are for example a methylthio, ethylthio, n-propylthio, isopropylthio, n-butylthio, isobutylthio, tert-butylthio or n-pentylthio, 2,2-dimethylpropylthio, 2-methylbutylthio or 3-methylbutylthio group.
C1-C5-Alkylthio groups are preferred. A methylthio or ethylthio group is particularly preferred.
The alkoxy and alkylthio groups described above may have on their alkyl groups the same substituents which have been described hereinbefore for the alkyl groups in general. Preferred substituents for alkoxy and alkylthio groups are selected independently of one another from halogen atoms (especially fluorine and/or chlorine), hydroxy and cyano groups.
The substituent -NR9R9a means for example -NH2, -NH (CH3) , -N ( CH3 ) 2, -NH ( C2H5 ) , -N ( C2H5 ) 2, -NH (C3H-7) ~ -N (C3H7) 2, -NH (C4H9) , -N (C4H9) 2, -NH (C5H11) , -N (C5H11) 2, -NH (CO) CH3r NH ( CO ) C2H5, -NH ( CO ) C3H7, -NH ( CO ) C4H9r -NH ( CO ) C5H11.
The cycloalkyl group means a saturated cyclic group which is optionally substituted by one or more groups selected from hydroxy groups, halogen atoms, (C1-C5)-alkyl groups, (C1-C5) -alkoxy groups, -NR9R9a groups, -COOR13 groups, -CHO, cyano and has 3 to 7 ring carbon atoms such as, for example, cyclopropyl, methyl-cyclopropyl, cyclobutyl, methylcyclobutyl, cyclopentyl, methylcyclopentyl, cyclohexyl, methylcyclohexyl, cycloheptyl, methylcycloheptyl.
A (C1-C$) alkyl- (C3-C7) cycloalkyl group R5 means a cycloalkyl group (as defined above) which is linked via a straight-chain or branched (C1-C$)-alkyl unit (as defined above) to the ring system. Examples of such groups are - (CH2) -cycloalkyl, - (C2H4) -cycloalkyl, - (C3H6) -cycloalkyl, - (C4H8) -cycloalkyl, - (C5H10-cyclo-alkyl, where cycloalkyl is defined as described above.
A (C2-C8) alkenyl- (C3-C7) cycloalkyl group R5 means a cycloalkyl group (as defined above) which is linked via a straight-chain or branched (CZ-C8)-alkenyl unit to the ring system. Examples of such groups are -(CH=CH)-cycloalkyl, - [C (CH3) =CH] -cycloalkyl, -[CH=C(CH3)]-cycloalkyl, -(CH=CH-CH2)-cycloalkyl, -(CH2-CH=CH)-cycloalkyl, - (CH=CH-CH2-CH2) -cycloalkyl, - (CHZ-CH=CH-CH2) -cycloalkyl, - (CH2-CH2-CH=CH) -cycloalkyl, - (C (CH3) =CH-CHZ) -cycloalkyl, - (CH=C (CH3) -CH2) -cyclo-alkyl.
An alkylidene or exo alkylidene group means a group having 1 to 10 carbon atoms which is bonded via an exo double bond to the system (ring or chain) . (C1-C5) - and (C1-C3)-alkylidene is preferred, and exo methylene is particularly preferred.
The heterocyclyl group is a cyclic, non-aromatic group comprising one or more heteroatoms and may be for example pyrrolidine, imidazolidine, pyrazolidine, piperidine. Perhydroquinoline and perhydroisoquinoline are also included in the heterocyclyl groups of the invention.
Examples of suitable substituents for heterocyclyl and heteroaryl groups are substituents from the following group: optionally substituted C1-C5-alkyl groups, hydroxy, (C1-C5) -alkoxy, -NR9R9a, halogen, cyano, -C00R13, -CHO. The substituents may optionally also be bonded to the nitrogen atom of the heterocyclyl or heteroaryl group; N-oxides are also included in the definition.
Aryl groups in the context of the invention are aromatic or partly aromatic carbocyclic groups having 6 to 14 carbon atoms which have one ring, such as, for example, phenyl or phenylene, or a plurality of fused rings, such as, for example, naphthyl or anthranyl.
Examples which may be mentioned are phenyl, naphthyl, tetralinyl, anthranyl, indanyl, and indenyl. The optionally substituted phenyl group and the naphthyl group are preferred.
The aryl groups may be substituted at any suitable position leading to a stable compound by one or more radicals from the group of hydroxy, halogen, C1-C5-alkyl which is optionally substituted by 1 to 3 hydroxy groups or -COOR13 groups, or C1-C5-alkoxy, cyano, -CF3 and nitro.
The aryl groups may be partly hydrogenated and then, in addition or as alternative to the substituents detailed above, also carry keto andlor exo alkylidene. Partly hydrogenated phenyl means for example cyclohexadienyl, cyclohexenyl, cyclohexyl. A partly hydrogenated substituted naphthalene system is for example 1-tetralone or 2-tetralone.
A(C1-C8)alkylaryl group is an aryl group as already described above which is linked via a straight-chain or branched (C1-C8)-alkyl unit (as defined above) to the ring system.
A(C2-C&)alkenylaryl group is an aryl group as already described above which is linked via a straight-chain or branched (C2-C8) -alkenyl unit (as defined above) to the ring system.
A(CZ-C8)alkynylaryl group is an aryl group as already described above which is linked via a straight-chain or branched (C2-C8) -alkynyl unit (as defined above) to the ring system.
Examples which may be mentioned are phenyl, naphthyl, tetralinyl, anthranyl, indanyl, and indenyl. The optionally substituted phenyl group and the naphthyl group are preferred.
The aryl groups may be substituted at any suitable position leading to a stable compound by one or more radicals from the group of hydroxy, halogen, C1-C5-alkyl which is optionally substituted by 1 to 3 hydroxy groups or -COOR13 groups, or C1-C5-alkoxy, cyano, -CF3 and nitro.
The aryl groups may be partly hydrogenated and then, in addition or as alternative to the substituents detailed above, also carry keto andlor exo alkylidene. Partly hydrogenated phenyl means for example cyclohexadienyl, cyclohexenyl, cyclohexyl. A partly hydrogenated substituted naphthalene system is for example 1-tetralone or 2-tetralone.
A(C1-C8)alkylaryl group is an aryl group as already described above which is linked via a straight-chain or branched (C1-C8)-alkyl unit (as defined above) to the ring system.
A(C2-C&)alkenylaryl group is an aryl group as already described above which is linked via a straight-chain or branched (C2-C8) -alkenyl unit (as defined above) to the ring system.
A(CZ-C8)alkynylaryl group is an aryl group as already described above which is linked via a straight-chain or branched (C2-C8) -alkynyl unit (as defined above) to the ring system.
The mono- or bicyclic heteroaryl group may optionally comprise 1 to 9 groups selected from nitrogen atoms, oxygen atoms, sulfur atoms or keto groups, of which a maximum of 4 nitrogen atoms, a maximum of 2 oxygen atoms, a maximum of 2 sulfur atoms and/or a maximum of 2 keto groups may be present. Every subcombination of these groups is possible. The heteroaryl group may be hydrogenated at one or more positions.
Monocyclic heteroaryl groups may be for example pyridine, pyrazine, pyrimidine, pyridazine, triazine, azaindolizine, 2H- and 4H-pyran, 2H- and 4H-thiopyran, furan, thiophene, 1H- and 4H-pyrazole, 1H- and 2H-pyrrole, oxazole, thiazole, furazan, 1H- and 4H-imidazole, isoxazole, isothiazole, oxadiazole, triazole, tetrazole, thiadiazole.
Bicyclic heteroaryl groups may be for example phthalidyl, thiophthalidyl, indolyl, isoindolyl, dihydroindolyl, dihydroisoindolyl, indazolyl, benzothiazolyl, indolonyl, dihydroindolonyl, isoindolonyl, dihydroisoindolonyl, benzofuranyl, benzimidazolyl, benzo[b]thienyl, benzo[c]thienyl, dihydroisoquinolinyl, dihydroquinolinyl, benzoxazinonyl, phthalazinonyl, dihydrophthalazinonyl, quinolinyl, isoquinolinyl, quinolonyl, isoquinolonyl, quinazolinyl, quinoxalinyl, cinnolinyl, phthalazinyl, dihydrophthalazinyl, 1,7- or 1,8-naphthyridinyl, coumarinyl, isocoumarinyl, indolizinyl, isobenzofuranyl, azaindolyl, azaisoindolyl, pyrazolo[1,5-a]pyridinyl, furanopyridyl, furanopyrimidinyl, furanopyrazinyl, furanopyridazinyl, dihydrobenzofuranyl, dihydrofuranopyridyl, dihydrofuranopyrimidinyl, dihydrofuranopyrazinyl, dihydrofuranopyridazinyl, dihydrobenzofuranyl group.
If the heteroaryl groups are partly or completely hydrogenated, the present invention includes compounds of the general formula (I) in which R3 is for example tetrahydropyranyl, 2H-pyranyl, 4H-pyranyl, piperidyl, tetrahydropyridyl, dihydropyridyl, 1H-pyridin-2-onyl, 1H-pyridin-4-onyl, 4-aminopyridyl, 1H-pyridin-4-ylideneaminyl, chromanyl, isochromanyl, thiochromanyl, decahydroquinolinyl, tetrahydroquinolinyl, dihydro-quinolinyl, 5,6,7,8-tetrahydro-lH-quinolin-4-onyl, decahydroisoquinolinyl, tetrahydroisoquinolinyl, dihydroisoquinolinyl, 3,4-dihydro-2H-benz[1,4]oxazinyl, 1,2-dihydro[1,3]benzoxazin-4-onyl, 3,4-dihydrobenz-[1,4]oxazin-4-onyl, 3,4-dihydro-2H-benzo[1,4]thiazinyl, 4H-benzo[1,4]thiazinyl, 1,2,3,4-tetrahydroquinoxalinyl, 1H-cinnolin-4-onyl, 3H-quinozolin-4-onyl, 1H-quinazolin-4-onyl, 3,4-dihydro-lH-quinoxalin-2-onyl, 2,3-1,2,3,4-tetrahydro[1,5]naphthyridinyl, dihydro-1H-[1,5]naphthyridyl, 1H-[1,5]naphthyrid-4-onyl , 5,6,7,8-tetrahydro-lH-naphthyridin-4-onyl, 1,2-dihydropyrido[3,2-d][1,3]oxazin-4-onyl, octahydro-1H-indolyl, 2,3-dihydro-lH-indolyl, octahydro-2H-isoindolyl, 1,3-dihydro-2H-isoindolyl, 1,2-dihydroindazolyl, 1H-pyrrolo[2,3-b]pyridyl, 2,3-dihydro-lH-pyrrolo[2,3-b]pyridyl, 2,2-dihydro-lH-pyrrolo[2,3-b]pyridin-3-onyl.
The mono- or bicyclic heteroaryl group may optionally be substituted by one or more substituents selected from C1-C5-alkyl groups which are optionally substituted by 1 to 3 hydroxy groups or 1 to 3-COOR13 groups, or Cl-C5-alkoxy groups, halogen atoms, and/or exo methylene groups. The substituents may, if possible, optionally also be bonded directly to the heteroatom (e.g. to the nitrogen atom). The present invention also includes N-oxides.
A(C1-C8) alkylheteroaryl group is a heteroaryl group as already described above which is linked via a straight-chain or branched (C1-C8) -alkyl unit (as defined above) to the ring system.
Monocyclic heteroaryl groups may be for example pyridine, pyrazine, pyrimidine, pyridazine, triazine, azaindolizine, 2H- and 4H-pyran, 2H- and 4H-thiopyran, furan, thiophene, 1H- and 4H-pyrazole, 1H- and 2H-pyrrole, oxazole, thiazole, furazan, 1H- and 4H-imidazole, isoxazole, isothiazole, oxadiazole, triazole, tetrazole, thiadiazole.
Bicyclic heteroaryl groups may be for example phthalidyl, thiophthalidyl, indolyl, isoindolyl, dihydroindolyl, dihydroisoindolyl, indazolyl, benzothiazolyl, indolonyl, dihydroindolonyl, isoindolonyl, dihydroisoindolonyl, benzofuranyl, benzimidazolyl, benzo[b]thienyl, benzo[c]thienyl, dihydroisoquinolinyl, dihydroquinolinyl, benzoxazinonyl, phthalazinonyl, dihydrophthalazinonyl, quinolinyl, isoquinolinyl, quinolonyl, isoquinolonyl, quinazolinyl, quinoxalinyl, cinnolinyl, phthalazinyl, dihydrophthalazinyl, 1,7- or 1,8-naphthyridinyl, coumarinyl, isocoumarinyl, indolizinyl, isobenzofuranyl, azaindolyl, azaisoindolyl, pyrazolo[1,5-a]pyridinyl, furanopyridyl, furanopyrimidinyl, furanopyrazinyl, furanopyridazinyl, dihydrobenzofuranyl, dihydrofuranopyridyl, dihydrofuranopyrimidinyl, dihydrofuranopyrazinyl, dihydrofuranopyridazinyl, dihydrobenzofuranyl group.
If the heteroaryl groups are partly or completely hydrogenated, the present invention includes compounds of the general formula (I) in which R3 is for example tetrahydropyranyl, 2H-pyranyl, 4H-pyranyl, piperidyl, tetrahydropyridyl, dihydropyridyl, 1H-pyridin-2-onyl, 1H-pyridin-4-onyl, 4-aminopyridyl, 1H-pyridin-4-ylideneaminyl, chromanyl, isochromanyl, thiochromanyl, decahydroquinolinyl, tetrahydroquinolinyl, dihydro-quinolinyl, 5,6,7,8-tetrahydro-lH-quinolin-4-onyl, decahydroisoquinolinyl, tetrahydroisoquinolinyl, dihydroisoquinolinyl, 3,4-dihydro-2H-benz[1,4]oxazinyl, 1,2-dihydro[1,3]benzoxazin-4-onyl, 3,4-dihydrobenz-[1,4]oxazin-4-onyl, 3,4-dihydro-2H-benzo[1,4]thiazinyl, 4H-benzo[1,4]thiazinyl, 1,2,3,4-tetrahydroquinoxalinyl, 1H-cinnolin-4-onyl, 3H-quinozolin-4-onyl, 1H-quinazolin-4-onyl, 3,4-dihydro-lH-quinoxalin-2-onyl, 2,3-1,2,3,4-tetrahydro[1,5]naphthyridinyl, dihydro-1H-[1,5]naphthyridyl, 1H-[1,5]naphthyrid-4-onyl , 5,6,7,8-tetrahydro-lH-naphthyridin-4-onyl, 1,2-dihydropyrido[3,2-d][1,3]oxazin-4-onyl, octahydro-1H-indolyl, 2,3-dihydro-lH-indolyl, octahydro-2H-isoindolyl, 1,3-dihydro-2H-isoindolyl, 1,2-dihydroindazolyl, 1H-pyrrolo[2,3-b]pyridyl, 2,3-dihydro-lH-pyrrolo[2,3-b]pyridyl, 2,2-dihydro-lH-pyrrolo[2,3-b]pyridin-3-onyl.
The mono- or bicyclic heteroaryl group may optionally be substituted by one or more substituents selected from C1-C5-alkyl groups which are optionally substituted by 1 to 3 hydroxy groups or 1 to 3-COOR13 groups, or Cl-C5-alkoxy groups, halogen atoms, and/or exo methylene groups. The substituents may, if possible, optionally also be bonded directly to the heteroatom (e.g. to the nitrogen atom). The present invention also includes N-oxides.
A(C1-C8) alkylheteroaryl group is a heteroaryl group as already described above which is linked via a straight-chain or branched (C1-C8) -alkyl unit (as defined above) to the ring system.
A(CZ-C8)alkenylheteroaryl group is a heteroaryl group as already described above which is linked via a straight-chain or branched (CZ-C8)-alkenyl unit (as defined above) to the ring system.
A(C2-C$)alkynylheteroaryl group is a heteroaryl group as already described above which is linked via a straight-chain or branched (C2-Ca)-alkynyl unit (as defined above) to the ring system.
A(C1-Ca)alkylheterocyclyl group is a heterocyclyl group as already described above which is linked via a straight-chain or branched (C1-C$)-alkyl unit (as defined above) to the ring system.
A(CZ-C8)alkenylheterocyclyl group is a heterocyclyl group as already described above which is linked via a straight-chain or branched (CZ-C8)-alkenyl unit (as defined above) to the ring system.
Suitable hydroxy protective groups are all conventional hydroxy protective groups known to the skilled worker, in particular silyl ethers or esters of organic C1-Clo acids, C1-C5 ethers, benzyl ethers or benzyl esters.
Conventional hydroxy protective groups are described in detail in T.W. Greene, P.G.M. Wuts "Protective Groups in Organic Synthesis", 2nd edition, John Wiley & Sons, 1991). The protective groups are preferably alkyl-, aryl- or mixed alkylaryl-substituted silyl groups, e.g.
the trimethylsilyl (TNIS), triethylsilyl (TES), tert-butyldimethylsilyl (TBDMS), tert-butyldiphenylsilyl (TBDPS) or triisopropylsilyl groups (TIPS) or other customary hydroxy protective groups (e.g.
methoxymethyl, methoxyethoxymethyl, ethoxyethyl, tetrahydrofuranyl, tetrahydropyranyl groups).
The compounds of the invention of the general formula (I) may, owing to the presence of centers of asymmetry, exist as stereoisomers. The present invention relates to all possible diastereoisomers both as racemates and in enantiopure form. The term stereoisomers also includes all possible diastereoisomers and regioisomers and tautomers (e.g. keto-enol tautomers) in which the stereoisomers of the invention may exist, and to which the invention therefore likewise relates.
The compounds of the invention may also be in the form of salts with pharmacologically acceptable anions, for example in the form of the hydrochloride, sulfate, nitrate, phosphate, pivalate, maleate, fumarate, tartrate, benzoate, mesylate, citrate or succinate.
The invention also includes pharmacologically suitable derivatives or prodrugs of the compounds of the general formula (I). Derivatives or prodrugs refers for example to esters, ethers or amides of the compounds of the general formula (I) or other compounds which metabolize in the body to compounds of the general formula (I).
Suitable compounds are listed for example in Hans Bundgaard (Editor), Design of Prodrugs, Elsevier, Amsterdam 1985.
Preferred embodiments A subgroup of compounds of the invention of the general formula (I) are those compounds in which R' and R8 are independently of one another a hydrogen atom, a halogen atom, an optionally substituted (C1-Clo)-alkyl group, a cyano group, together a(C1-Clo)-alkylidene group or together with the carbon atom of the tetrahydro-naphthalene system an optionally substituted (C3-C6)-cycloalkyl ring.
A further subgroup of compounds of the invention of the general formula (I) are those compounds in which R6 and R' together form a fused five- to eight-membered saturated or unsaturated carbocycle or heterocycle which is optionally substituted by 1 to 2 keto groups, 1 to 2 (C1-C5) -alkyl groups, 1 to 2 (C1-C5) -alkoxy groups, and/or 1 to 4 halogen atoms.
A further subgroup of compounds of the invention of the general formula (I) are those compounds in which R1 and R8 together form a fused five- to eight-membered saturated or unsaturated carbocycle or heterocycle which is optionally substituted by 1 to 2 keto groups, 1 to 2 (C1-C5) -alkyl groups, 1 to 2 (C1-C5) -alkoxy groups, and/or 1 to 4 halogen atoms.
A further subgroup of compounds of the invention of the general formula (I) are those compounds in which R' and R2 are independently of one another a hydrogen atom, a hydroxy group, a halogen atom, an optionally substituted (C1-C10) -alkyl group, a (C1-C10) -alkoxy group, a (C1-C10) -alkylthio group, a (C1-CS) -perfluoroalkyl group, a cyano group, a nitro group, or an -NR9R9a group.
A further subgroup of compounds of the invention of the general formula (I) are those compounds in which or R1 and R2 together form a group selected from the groups -0- (CH2 ) n-0, -0- (CH2 ) n-CH2-, -O-CH=CH-, - ( CH2 ) n+2- r -NH- (CH2) n+l-, -N (C1-C3-alkyl) - (CH2) õ+1- and -NH-N=CH-, where n = 1 or 2, and the terminal oxygen atoms and/or carbon atoms and/or nitrogen atoms are linked to directly adjacent ring carbon atoms.
A preferred group of compounds of the general formula (I) are those compounds in which X is a group -C (=0) -, -C (=0 ) -NH-, -SO2- or -CH2- .
A further preferred group of compounds of the general formula (I) are those compounds in which R4 is a hydroxy group or a group -OR10. Those compounds in which R 4 is a hydroxy group are particularly preferred.
A(C2-C$)alkynylheteroaryl group is a heteroaryl group as already described above which is linked via a straight-chain or branched (C2-Ca)-alkynyl unit (as defined above) to the ring system.
A(C1-Ca)alkylheterocyclyl group is a heterocyclyl group as already described above which is linked via a straight-chain or branched (C1-C$)-alkyl unit (as defined above) to the ring system.
A(CZ-C8)alkenylheterocyclyl group is a heterocyclyl group as already described above which is linked via a straight-chain or branched (CZ-C8)-alkenyl unit (as defined above) to the ring system.
Suitable hydroxy protective groups are all conventional hydroxy protective groups known to the skilled worker, in particular silyl ethers or esters of organic C1-Clo acids, C1-C5 ethers, benzyl ethers or benzyl esters.
Conventional hydroxy protective groups are described in detail in T.W. Greene, P.G.M. Wuts "Protective Groups in Organic Synthesis", 2nd edition, John Wiley & Sons, 1991). The protective groups are preferably alkyl-, aryl- or mixed alkylaryl-substituted silyl groups, e.g.
the trimethylsilyl (TNIS), triethylsilyl (TES), tert-butyldimethylsilyl (TBDMS), tert-butyldiphenylsilyl (TBDPS) or triisopropylsilyl groups (TIPS) or other customary hydroxy protective groups (e.g.
methoxymethyl, methoxyethoxymethyl, ethoxyethyl, tetrahydrofuranyl, tetrahydropyranyl groups).
The compounds of the invention of the general formula (I) may, owing to the presence of centers of asymmetry, exist as stereoisomers. The present invention relates to all possible diastereoisomers both as racemates and in enantiopure form. The term stereoisomers also includes all possible diastereoisomers and regioisomers and tautomers (e.g. keto-enol tautomers) in which the stereoisomers of the invention may exist, and to which the invention therefore likewise relates.
The compounds of the invention may also be in the form of salts with pharmacologically acceptable anions, for example in the form of the hydrochloride, sulfate, nitrate, phosphate, pivalate, maleate, fumarate, tartrate, benzoate, mesylate, citrate or succinate.
The invention also includes pharmacologically suitable derivatives or prodrugs of the compounds of the general formula (I). Derivatives or prodrugs refers for example to esters, ethers or amides of the compounds of the general formula (I) or other compounds which metabolize in the body to compounds of the general formula (I).
Suitable compounds are listed for example in Hans Bundgaard (Editor), Design of Prodrugs, Elsevier, Amsterdam 1985.
Preferred embodiments A subgroup of compounds of the invention of the general formula (I) are those compounds in which R' and R8 are independently of one another a hydrogen atom, a halogen atom, an optionally substituted (C1-Clo)-alkyl group, a cyano group, together a(C1-Clo)-alkylidene group or together with the carbon atom of the tetrahydro-naphthalene system an optionally substituted (C3-C6)-cycloalkyl ring.
A further subgroup of compounds of the invention of the general formula (I) are those compounds in which R6 and R' together form a fused five- to eight-membered saturated or unsaturated carbocycle or heterocycle which is optionally substituted by 1 to 2 keto groups, 1 to 2 (C1-C5) -alkyl groups, 1 to 2 (C1-C5) -alkoxy groups, and/or 1 to 4 halogen atoms.
A further subgroup of compounds of the invention of the general formula (I) are those compounds in which R1 and R8 together form a fused five- to eight-membered saturated or unsaturated carbocycle or heterocycle which is optionally substituted by 1 to 2 keto groups, 1 to 2 (C1-C5) -alkyl groups, 1 to 2 (C1-C5) -alkoxy groups, and/or 1 to 4 halogen atoms.
A further subgroup of compounds of the invention of the general formula (I) are those compounds in which R' and R2 are independently of one another a hydrogen atom, a hydroxy group, a halogen atom, an optionally substituted (C1-C10) -alkyl group, a (C1-C10) -alkoxy group, a (C1-C10) -alkylthio group, a (C1-CS) -perfluoroalkyl group, a cyano group, a nitro group, or an -NR9R9a group.
A further subgroup of compounds of the invention of the general formula (I) are those compounds in which or R1 and R2 together form a group selected from the groups -0- (CH2 ) n-0, -0- (CH2 ) n-CH2-, -O-CH=CH-, - ( CH2 ) n+2- r -NH- (CH2) n+l-, -N (C1-C3-alkyl) - (CH2) õ+1- and -NH-N=CH-, where n = 1 or 2, and the terminal oxygen atoms and/or carbon atoms and/or nitrogen atoms are linked to directly adjacent ring carbon atoms.
A preferred group of compounds of the general formula (I) are those compounds in which X is a group -C (=0) -, -C (=0 ) -NH-, -SO2- or -CH2- .
A further preferred group of compounds of the general formula (I) are those compounds in which R4 is a hydroxy group or a group -OR10. Those compounds in which R 4 is a hydroxy group are particularly preferred.
A further preferred group of compounds of the general formula (I) are those compounds in which R5 is a (C1-C5) -alkyl group or a partly or completely fluorinated (Cl-C5) -alkyl group, an aryl group, a (C1-C8) alkylaryl group, a (CZ-C8) alkenylaryl group, a (C3-C7) cycloalkyl gorup, a (C1-C8) alkyl (C3-C-,) cycloalkyl group or a (C2-C8) alkenyl (C3-C7) cycloalkyl group.
Compounds which are preferred in this connection are those in which R5 is a(C1-C5)-alkyl group or a partly or completely fluorinated (C1-C5)-alkyl group.
Particularly preferred compounds in this connection are those in which R5 is a trifluoromethyl or a pentafluoroethyl group.
A further preferred group of compounds of the general formula (I) are those compounds in which R' is a halogen atom or an optionally substituted methyl or ethyl group.
A further preferred group of compounds of the general formula (I) are those compounds in which R' and R8 are each a methyl group, or together with the carbon atom of the tetrahydronaphthalene system form a cyclopropyl group. Particularly preferred compounds are those in which R7 and R8 are each a methyl group.
A further preferred group of compounds of the general formula (I) are those compounds in which R3 is an optionally substituted aryl or heteroaryl group.
Particularly preferred compounds in this connection are those in which the aryl or heteroaryl group is selected from the group consisting of naphthyl, benzofuranyl, pyrazolo[1,5-a]pyridinyl, phenyl, phthalidyl, isoindolyl, dihydroindolyl, dihydroisoindolyl, dihydroisoquinolinyl, thiophthalidyl, benzoxazinonyl, phthalazinonyl, quinolinyl, isoquinolinyl, quinolonyl, isoquinolonyl, indazolyl, benzothiazolyl, chromanyl, isochromanyl, quinazolinyl, quinoxalinyl, cinnolinyl, phthalazinyl, 1,7- or 1,8-naphthyridinyl, dihydroindolonyl, dihydroisoindolonyl, benzimidazole or indolyl. Particularly preferred groups in this connection are naphthyl, benzofuranyl, quinoxalinyl, and pyrazolo[1,5-a]pyridinyl.
A subgroup of compounds of the general formula (I) are those compounds in which the substituents R11 and R' 2 are each independently of one another a hydrogen atom, a halogen atom, in particular fluorine, a cyano or a methoxy group.
In a preferred subgroup, the substituents R" and R12 are each a hydrogen atom.
A particularly preferred group of compounds of the general formula (I) as defined above are those compounds in which R1, R2, R11, and R12 are independently of one another a hydrogen atom, a halogen atom, a hydroxy group, an optionally substituted (C1-C10)-alkyl group, or a (C1-C10) -alkoxy group, R3 is an optionally substituted aryl or heteroaryl group, R4 is a hydroxy group, an -OR10 group or an -O (CO) Rl0 group, R5 is a(C1-C1 )alkyl group which is optionally partly or completely fluorinated, R6 is a hydrogen atom, a halogen atom or an optionally substituted (C1-C10) -alkyl group, R7 and Ra are independently of one another an optionally substituted (C1-C10) -alkyl group, together a (C1-C10) -alkylidene group or together with the carbon atom of the tetrahydronaphthalene system an optionally substituted (C3-C6) -cycloalkyl ring, R10 is a (Cl-C10) -alkyl group, and X is the group -C(=O)-, -C(=O)-NH-, -S(O)m- (where m equals 1 or 2), or -(CH2)p- (where p equals 1, 2 or 3).
A very particularly preferred group of compounds of the general formula (I) as defined above are those compounds in which R1 and R 2 are each independently of one another a hydrogen atom, a hydroxy group or a methoxy group, R" and R12 are each a hydrogen atom, R3 is a naphthyl, benzofuranyl, quinoxalinyl or pyrazolo[1,5-a]pyridinyl group, R4 is a hydroxy group, R5 is a trifluoromethyl group, R6 is a hydrogen atom, R' and R8 are each a methyl group, and X is one of the groups -C(=O)-, -C(=0)-NH-, -SOZ- and -CH2-.
Every further possible combination of the abovementioned subgroups and of substituents indicated as preferred with their general and/or specific meanings is likewise to be regarded as encompassed by the present invention.
Preparation processes The compounds of the invention of the general formula (I) can be obtained in various ways. The preparation processes described below likewise form a part of the present invention.
Unless indicated otherwise, the substituents used in the process descriptions below have the same meaning as above in the section "Brief description of the invention", including the definitions stated in the section "Detailed description of the invention".
One process according to the invention (process A) for preparing compounds of the general formula (I) is characterized in that a) an open-chain carbonyl compound of the general formula (II) R8 R' R5 R O
R~
z ~
Ri~ R~2 (II) is cyclized where appropriate with addition of an inorganic or organic acid or Lewis acid to a compound of the general formula (III) R8 R ' R~ ~ R12 R
OH (III) , b) the compound of the general formula (III) is converted by processes known in the art for replacing the hydroxy group by the amino group into a compound of the general formula (IV) R$ R 7 (IV);
and c) the compound of the general formula (IV) is converted by reaction with a compound selected from compounds of the general formulae R3-X-Nu (where Nu is a nucleofugic group), R3-N=C=O or R3-N=C=S, and where appropriate subsequent replacement of a carbonyl oxygen atom by sulfur by processes known in the art, into a compound of the general formula (I).
The substituents R1 to R12 have the meanings indicated above.
Compounds which are preferred in this connection are those in which R5 is a(C1-C5)-alkyl group or a partly or completely fluorinated (C1-C5)-alkyl group.
Particularly preferred compounds in this connection are those in which R5 is a trifluoromethyl or a pentafluoroethyl group.
A further preferred group of compounds of the general formula (I) are those compounds in which R' is a halogen atom or an optionally substituted methyl or ethyl group.
A further preferred group of compounds of the general formula (I) are those compounds in which R' and R8 are each a methyl group, or together with the carbon atom of the tetrahydronaphthalene system form a cyclopropyl group. Particularly preferred compounds are those in which R7 and R8 are each a methyl group.
A further preferred group of compounds of the general formula (I) are those compounds in which R3 is an optionally substituted aryl or heteroaryl group.
Particularly preferred compounds in this connection are those in which the aryl or heteroaryl group is selected from the group consisting of naphthyl, benzofuranyl, pyrazolo[1,5-a]pyridinyl, phenyl, phthalidyl, isoindolyl, dihydroindolyl, dihydroisoindolyl, dihydroisoquinolinyl, thiophthalidyl, benzoxazinonyl, phthalazinonyl, quinolinyl, isoquinolinyl, quinolonyl, isoquinolonyl, indazolyl, benzothiazolyl, chromanyl, isochromanyl, quinazolinyl, quinoxalinyl, cinnolinyl, phthalazinyl, 1,7- or 1,8-naphthyridinyl, dihydroindolonyl, dihydroisoindolonyl, benzimidazole or indolyl. Particularly preferred groups in this connection are naphthyl, benzofuranyl, quinoxalinyl, and pyrazolo[1,5-a]pyridinyl.
A subgroup of compounds of the general formula (I) are those compounds in which the substituents R11 and R' 2 are each independently of one another a hydrogen atom, a halogen atom, in particular fluorine, a cyano or a methoxy group.
In a preferred subgroup, the substituents R" and R12 are each a hydrogen atom.
A particularly preferred group of compounds of the general formula (I) as defined above are those compounds in which R1, R2, R11, and R12 are independently of one another a hydrogen atom, a halogen atom, a hydroxy group, an optionally substituted (C1-C10)-alkyl group, or a (C1-C10) -alkoxy group, R3 is an optionally substituted aryl or heteroaryl group, R4 is a hydroxy group, an -OR10 group or an -O (CO) Rl0 group, R5 is a(C1-C1 )alkyl group which is optionally partly or completely fluorinated, R6 is a hydrogen atom, a halogen atom or an optionally substituted (C1-C10) -alkyl group, R7 and Ra are independently of one another an optionally substituted (C1-C10) -alkyl group, together a (C1-C10) -alkylidene group or together with the carbon atom of the tetrahydronaphthalene system an optionally substituted (C3-C6) -cycloalkyl ring, R10 is a (Cl-C10) -alkyl group, and X is the group -C(=O)-, -C(=O)-NH-, -S(O)m- (where m equals 1 or 2), or -(CH2)p- (where p equals 1, 2 or 3).
A very particularly preferred group of compounds of the general formula (I) as defined above are those compounds in which R1 and R 2 are each independently of one another a hydrogen atom, a hydroxy group or a methoxy group, R" and R12 are each a hydrogen atom, R3 is a naphthyl, benzofuranyl, quinoxalinyl or pyrazolo[1,5-a]pyridinyl group, R4 is a hydroxy group, R5 is a trifluoromethyl group, R6 is a hydrogen atom, R' and R8 are each a methyl group, and X is one of the groups -C(=O)-, -C(=0)-NH-, -SOZ- and -CH2-.
Every further possible combination of the abovementioned subgroups and of substituents indicated as preferred with their general and/or specific meanings is likewise to be regarded as encompassed by the present invention.
Preparation processes The compounds of the invention of the general formula (I) can be obtained in various ways. The preparation processes described below likewise form a part of the present invention.
Unless indicated otherwise, the substituents used in the process descriptions below have the same meaning as above in the section "Brief description of the invention", including the definitions stated in the section "Detailed description of the invention".
One process according to the invention (process A) for preparing compounds of the general formula (I) is characterized in that a) an open-chain carbonyl compound of the general formula (II) R8 R' R5 R O
R~
z ~
Ri~ R~2 (II) is cyclized where appropriate with addition of an inorganic or organic acid or Lewis acid to a compound of the general formula (III) R8 R ' R~ ~ R12 R
OH (III) , b) the compound of the general formula (III) is converted by processes known in the art for replacing the hydroxy group by the amino group into a compound of the general formula (IV) R$ R 7 (IV);
and c) the compound of the general formula (IV) is converted by reaction with a compound selected from compounds of the general formulae R3-X-Nu (where Nu is a nucleofugic group), R3-N=C=O or R3-N=C=S, and where appropriate subsequent replacement of a carbonyl oxygen atom by sulfur by processes known in the art, into a compound of the general formula (I).
The substituents R1 to R12 have the meanings indicated above.
Replacement of the hydroxy group by the amino group in step b) indicated above can be achieved for example by converting the compound of the general formula (III) by processes known in the art (nucleophilic substitution) into the corresponding azide, which can be reduced under suitable conditions to the primary amine of the general formula (IV).
A further possibility for introducing the amino group consists of reacting the compound of the general formula (III) with Burgess' reagent (Tetrahedron Lett.
2002, 43, 3887-3890) and subsequent cleavage of the resulting heterocycle, which is obtainable by processes known in the art.
The optional replacement of a carbonyl oxygen atom by sulfur which is described in step c) is known in the art and can be achieved for example by reaction with Lawesson's reagent or phosphorus pentasulfide.
Examples of suitable nucleofugic groups Nu in the compound R3-X-Nu used in step c) are halogen atoms or leaving groups such as, for example, the acetate, tosylate, mesylate or triflate group. The compounds R3-X-Nu thus belong for example to the classes of the halides of carboxylic acids, sulfonic acids, or sulfinic acids, or of mixed anhydrides of these acids, and to the esters of chloroformic acid, of toluenesulfonic acid, of methylsulfonic acid and of trifluoromethylsulfonic acid.
A further process according to the invention (process B) for preparing compounds of the general formula (I) consists of reacting a compound of the general formula (IV) as described above with a compound of the general formula R3-CHO, and reducing the resulting imine.
A further possibility for introducing the amino group consists of reacting the compound of the general formula (III) with Burgess' reagent (Tetrahedron Lett.
2002, 43, 3887-3890) and subsequent cleavage of the resulting heterocycle, which is obtainable by processes known in the art.
The optional replacement of a carbonyl oxygen atom by sulfur which is described in step c) is known in the art and can be achieved for example by reaction with Lawesson's reagent or phosphorus pentasulfide.
Examples of suitable nucleofugic groups Nu in the compound R3-X-Nu used in step c) are halogen atoms or leaving groups such as, for example, the acetate, tosylate, mesylate or triflate group. The compounds R3-X-Nu thus belong for example to the classes of the halides of carboxylic acids, sulfonic acids, or sulfinic acids, or of mixed anhydrides of these acids, and to the esters of chloroformic acid, of toluenesulfonic acid, of methylsulfonic acid and of trifluoromethylsulfonic acid.
A further process according to the invention (process B) for preparing compounds of the general formula (I) consists of reacting a compound of the general formula (IV) as described above with a compound of the general formula R3-CHO, and reducing the resulting imine.
Finally, a further process according to the invention (process C) for preparing compounds of the general formula (I) consists of reacting a compound of the general formula (IV) as described above with phosgene or thiophosgene, and subsequently reacting the resulting isocyanate or isothiocyanate with compounds of the general formula R3-OH or R3-NH2 to give a compound of the general formula (I), where X has the meaning -C(=O)-NH-, -C(=S)-NH- or -C(=O)-O- indicated in claim 1.
A further process according to the invention (process D) for preparing a compound of the general formula (I) is characterized in that a) a compound of the general formula (VI) R~ R 8 \ R6 (VI) where R8 is a (C1-Clo) -alkyl group, is reacted with an a-keto carboxylic acid or an a-keto carboxylic ester of the general formula R5-C(=O)-COOR13 in an ene reaction in the presence of an optionally chiral Lewis acid to give a compound of the general formula (VII) R R$ R' OH
R
(VII) in which R7 and R$ together have the meaning of a (C1-Clo) -alkylidene group, b) the compound of the general formula (VII) is reduced to an aldehyde of the general formula (IIa), R R$ R7 OH
O
R~ R12 (IIa) in which R' and R8 together have the meaning of a(C1-Clo)-alkylidene group, and c) the aldehyde (IIa) is converted in analogy to process A indicated above into a compound of the general formula (I) in which R7 and R8 together have the meaning of a (Cl-Clo) -alkylidene group.
The substituents R' to R' 3 have the meanings indicated above.
Processes for selective reduction of a carboxylic acid or of a carboxylic ester to the aldehyde, as used in step b) of process D, are known in the art.
It is optionally possible to include in process D
further reaction steps to modify R7 and R8. Thus, for example, the (C1-Clo)-alkylidene group in intermediate (IIa) can be hydrogenated, thus providing compounds of the general formula (I) in which one of the radicals R7 and R 8 has the meaning of a hydrogen atom, whereas the other radical is a(C1-Clo) -alkyl group.
The (C1-Clo)-alkylidene group in intermediate (IIa) can also be employed as substrate for a hydrohalogenation.
The final products of the synthesis resulting in this case are compounds of the general formula (I) in which one of the radicals R7 and R8 has the meaning of a halogen atom, or else the other radical is a(C1-Clo) -alkyl group.
Finally, it is also possible to carry out cycloaddition reactions on the (C1-Clo)-alkylidene group in intermediate (IIa). Particularly preferred in this connection are cyclopropanation reactions which afford as final products of the synthesis compounds of the general formula (I) in which the radicals R' and R8 have, together with the ring carbon atom, the meaning of an (optionally substituted) cyclopropane ring.
It is directly evident to the skilled worker that these modifications to the radicals R' and R8 in process D do not necessarily have to be carried out on intermediate (IIa) but can also where appropriate be carried out at a later time in the complete synthesis. These variations in the sequence of the reaction steps are likewise included in the present invention.
Biological activity The antiinflammatory effect of the compounds of the general formula (I) is tested in an animal experiment by testing in the croton oil-induced inflammation in the rat and mouse (J. Exp. Med. (1995), 182, 99-108).
For this purpose, croton oil is applied in ethanolic solution topically to the ears of the animals. The test substances are likewise administered topically or systemically at the same time as or two hours before the croton oil. After 16-24 hours, the ear weight is measured as a measure of the inflammatory edema, the peroxidase activity is measured as a measure of the migration in of granulocytes and the elastase activity is measured as a measure of the migration in of neutrophilic granulocytes. In this test, the compounds of the general formula (I) inhibit the three abovementioned parameters of inflammation both after topical and after systemic administration.
A further process according to the invention (process D) for preparing a compound of the general formula (I) is characterized in that a) a compound of the general formula (VI) R~ R 8 \ R6 (VI) where R8 is a (C1-Clo) -alkyl group, is reacted with an a-keto carboxylic acid or an a-keto carboxylic ester of the general formula R5-C(=O)-COOR13 in an ene reaction in the presence of an optionally chiral Lewis acid to give a compound of the general formula (VII) R R$ R' OH
R
(VII) in which R7 and R$ together have the meaning of a (C1-Clo) -alkylidene group, b) the compound of the general formula (VII) is reduced to an aldehyde of the general formula (IIa), R R$ R7 OH
O
R~ R12 (IIa) in which R' and R8 together have the meaning of a(C1-Clo)-alkylidene group, and c) the aldehyde (IIa) is converted in analogy to process A indicated above into a compound of the general formula (I) in which R7 and R8 together have the meaning of a (Cl-Clo) -alkylidene group.
The substituents R' to R' 3 have the meanings indicated above.
Processes for selective reduction of a carboxylic acid or of a carboxylic ester to the aldehyde, as used in step b) of process D, are known in the art.
It is optionally possible to include in process D
further reaction steps to modify R7 and R8. Thus, for example, the (C1-Clo)-alkylidene group in intermediate (IIa) can be hydrogenated, thus providing compounds of the general formula (I) in which one of the radicals R7 and R 8 has the meaning of a hydrogen atom, whereas the other radical is a(C1-Clo) -alkyl group.
The (C1-Clo)-alkylidene group in intermediate (IIa) can also be employed as substrate for a hydrohalogenation.
The final products of the synthesis resulting in this case are compounds of the general formula (I) in which one of the radicals R7 and R8 has the meaning of a halogen atom, or else the other radical is a(C1-Clo) -alkyl group.
Finally, it is also possible to carry out cycloaddition reactions on the (C1-Clo)-alkylidene group in intermediate (IIa). Particularly preferred in this connection are cyclopropanation reactions which afford as final products of the synthesis compounds of the general formula (I) in which the radicals R' and R8 have, together with the ring carbon atom, the meaning of an (optionally substituted) cyclopropane ring.
It is directly evident to the skilled worker that these modifications to the radicals R' and R8 in process D do not necessarily have to be carried out on intermediate (IIa) but can also where appropriate be carried out at a later time in the complete synthesis. These variations in the sequence of the reaction steps are likewise included in the present invention.
Biological activity The antiinflammatory effect of the compounds of the general formula (I) is tested in an animal experiment by testing in the croton oil-induced inflammation in the rat and mouse (J. Exp. Med. (1995), 182, 99-108).
For this purpose, croton oil is applied in ethanolic solution topically to the ears of the animals. The test substances are likewise administered topically or systemically at the same time as or two hours before the croton oil. After 16-24 hours, the ear weight is measured as a measure of the inflammatory edema, the peroxidase activity is measured as a measure of the migration in of granulocytes and the elastase activity is measured as a measure of the migration in of neutrophilic granulocytes. In this test, the compounds of the general formula (I) inhibit the three abovementioned parameters of inflammation both after topical and after systemic administration.
The binding of the substances to the glucocorticoid receptor (GR) and further steroid hormone receptors (mineral corticoid receptor (MR), progesterone receptor (PR) and androgen receptor (AR)) is examined with the aid of recombinantly prepared receptors. Cytosol preparations of Sf9 cells which had been infected with recombinant baculoviruses which code for the GR are employed for the binding studies. Compared with the reference substance [3H]-dexamethasone, the substances show a high affinity for the GR. Thus, an IC50(GR) =
36 nM and IC50 (PR) > 1 uM was measured for the compound of example 3L.
The essential molecular mechanism for the antiinflammatory effect of glucocorticoids is regarded as the GR-mediated inhibition of the transcription of cytokines, adhesion molecules, enzymes and other pro-inflammatory factors. This inhibition is brought about by an interaction of the GR with other transcription factors, e.g. AP-1 and NF-kappa-B (for review, see Cato ACB and Wade E, BioEssays 18, 371-378 1996).
The compounds of the invention of the general formula (I) inhibit the secretion, induced by lipopolysaccharide (LPS), of the cytokine IL-8 in the human THP-1 monocyte cell line. The concentration of the cytokines was determined in the supernatant using a commercially available ELISA kit. The compound of example 3E exhibited an IC50 ( IL8 ) 1}.imol inhibition at an 11% efficiency with regard to [3H]-dexamethasone as standard.
One of the commonest unwanted effects of a glucocorticoid therapy is the so-called "steroid diabetes" [cf. Hatz, HJ, Glucocorticoide:
Immunologische Grundlagen, Pharmakologie und Therapierichtlinien, Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart, 1998]. The cause of this is stimulation of gluconeogenesis in the liver by induction of the enzymes responsible therefor and by free amino acids resulting from the breakdown of proteins (catabolic effect of the glucocorticoids) . A
key enzyme in catabolic metabolism in the liver is tyrosine aminotransferase (TAT) . The activity of this enzyme can be determined by photometry on liver homogenates and represents a good measure of the unwanted metabolic effects of glucocorticoids. To measure the TAT induction, the animals are sacrificed 8 hours after administration of the test substances, the livers are removed, and the TAT activity in the homogenate is measured. In this test, the compounds of the general formula (I) induce, in doses in which they have antiinflammatory activity, tyrosine aminotransferase to only a small extent or not at all.
Medical indications Owing to their antiinflammatory and additional anti-allergic, immunosuppressive and antiproliferative effect, the compounds of the invention of the general formula (I) can be used as medicaments for the treatment or prophylaxis of the following pathological states in patients, especially mammals and preferably humans.
In this connection, the term "DISORDER" stands for the following indications:
(i) pulmonary disorders associated with inflammatory, allergic and/or proliferative processes:
- chronic obstructive lung disorders of any origin, especially bronchial asthma - bronchitis of varying origin - all types of restrictive lung disorders, especially allergic alveolitis, - all types of pulmonary edema, especially toxic pulmonary edema - sarcoidoses and granulomatoses, especially Boeck's disease (ii) rheumatic disorders/autoimmune diseases/joint disorders associated with inflammatory, allergic and/or proliferative processes:
- all types of rheumatic disorders, especially rheumatoid arthritis, acute rheumatic fever, polymyalgia rheumatica - reactive arthritis - inflammatory soft tissue disorders of other origin - arthritic symptoms associated with degenerative joint disorders (arthroses) - traumatic arthritides - collagenoses of any origin, e.g. systemic lupus erythematosus, scleroderma, polymyositis, dermatomyositis, Sjogren's syndrome, Still's syndrome, Felty's syndrome (iii) allergies associated with inflammatory and/or proliferative processes:
- all types of allergic reactions, e.g.
angioedema, hayfever, insect bite, allergic reactions to drugs, blood derivatives, contrast agents etc., anaphylactic shock, urticaria, contact dermatitis (iv) vessel inflammations (vasculitides) - polyarteritis nodosa, temporal arteritis, erythema nodosum (v) dermatological disorders associated with inflammatory, allergic and/or proliferative processes:
- atopic dermatitis (especially in children) - psoriasis - pityriasis rubra pilaris - erythematous disorders induced by various noxae, e.g. radiation, chemicals, burns, etc.
- bullous dermatoses - lichenoid disorders - pruritus (e.g. of allergic origin) - seborrheic eczema - rosacea - pemphigus vulgaris - erythema multiforme exudativum - balanitis - vulvitis - hair loss such as alopecia areata - cutaneous T-cell lymphomas (vi) renal disorders associated with inflammatory, allergic and/or proliferative processes:
- nephrotic syndrome - all nephritides (vii) liver disorders associated with inflammatory, allergic and/or proliferative processes:
- acute liver cell necrosis - acute hepatitis of varying origin, e.g.
viral, toxic, drug-induced - chronic aggressive and/or chronic intermittent hepatitis (viii) gastrointestinal disorders associated with inflammatory, allergic and/or proliferative processes:
- regional enteritis (Crohn's disease) - ulcerative colitis - gastritis - reflux esophagitis - gastroenteritides of other origin, e.g.
indigenous sprue (ix) proctological disorders associated with inflammatory, allergic and/or proliferative processes:
- anal eczema - fissures - hemorrhoids - idiopathic proctitis (x) ocular disorders associated with inflammatory, allergic and/or proliferative processes:
36 nM and IC50 (PR) > 1 uM was measured for the compound of example 3L.
The essential molecular mechanism for the antiinflammatory effect of glucocorticoids is regarded as the GR-mediated inhibition of the transcription of cytokines, adhesion molecules, enzymes and other pro-inflammatory factors. This inhibition is brought about by an interaction of the GR with other transcription factors, e.g. AP-1 and NF-kappa-B (for review, see Cato ACB and Wade E, BioEssays 18, 371-378 1996).
The compounds of the invention of the general formula (I) inhibit the secretion, induced by lipopolysaccharide (LPS), of the cytokine IL-8 in the human THP-1 monocyte cell line. The concentration of the cytokines was determined in the supernatant using a commercially available ELISA kit. The compound of example 3E exhibited an IC50 ( IL8 ) 1}.imol inhibition at an 11% efficiency with regard to [3H]-dexamethasone as standard.
One of the commonest unwanted effects of a glucocorticoid therapy is the so-called "steroid diabetes" [cf. Hatz, HJ, Glucocorticoide:
Immunologische Grundlagen, Pharmakologie und Therapierichtlinien, Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart, 1998]. The cause of this is stimulation of gluconeogenesis in the liver by induction of the enzymes responsible therefor and by free amino acids resulting from the breakdown of proteins (catabolic effect of the glucocorticoids) . A
key enzyme in catabolic metabolism in the liver is tyrosine aminotransferase (TAT) . The activity of this enzyme can be determined by photometry on liver homogenates and represents a good measure of the unwanted metabolic effects of glucocorticoids. To measure the TAT induction, the animals are sacrificed 8 hours after administration of the test substances, the livers are removed, and the TAT activity in the homogenate is measured. In this test, the compounds of the general formula (I) induce, in doses in which they have antiinflammatory activity, tyrosine aminotransferase to only a small extent or not at all.
Medical indications Owing to their antiinflammatory and additional anti-allergic, immunosuppressive and antiproliferative effect, the compounds of the invention of the general formula (I) can be used as medicaments for the treatment or prophylaxis of the following pathological states in patients, especially mammals and preferably humans.
In this connection, the term "DISORDER" stands for the following indications:
(i) pulmonary disorders associated with inflammatory, allergic and/or proliferative processes:
- chronic obstructive lung disorders of any origin, especially bronchial asthma - bronchitis of varying origin - all types of restrictive lung disorders, especially allergic alveolitis, - all types of pulmonary edema, especially toxic pulmonary edema - sarcoidoses and granulomatoses, especially Boeck's disease (ii) rheumatic disorders/autoimmune diseases/joint disorders associated with inflammatory, allergic and/or proliferative processes:
- all types of rheumatic disorders, especially rheumatoid arthritis, acute rheumatic fever, polymyalgia rheumatica - reactive arthritis - inflammatory soft tissue disorders of other origin - arthritic symptoms associated with degenerative joint disorders (arthroses) - traumatic arthritides - collagenoses of any origin, e.g. systemic lupus erythematosus, scleroderma, polymyositis, dermatomyositis, Sjogren's syndrome, Still's syndrome, Felty's syndrome (iii) allergies associated with inflammatory and/or proliferative processes:
- all types of allergic reactions, e.g.
angioedema, hayfever, insect bite, allergic reactions to drugs, blood derivatives, contrast agents etc., anaphylactic shock, urticaria, contact dermatitis (iv) vessel inflammations (vasculitides) - polyarteritis nodosa, temporal arteritis, erythema nodosum (v) dermatological disorders associated with inflammatory, allergic and/or proliferative processes:
- atopic dermatitis (especially in children) - psoriasis - pityriasis rubra pilaris - erythematous disorders induced by various noxae, e.g. radiation, chemicals, burns, etc.
- bullous dermatoses - lichenoid disorders - pruritus (e.g. of allergic origin) - seborrheic eczema - rosacea - pemphigus vulgaris - erythema multiforme exudativum - balanitis - vulvitis - hair loss such as alopecia areata - cutaneous T-cell lymphomas (vi) renal disorders associated with inflammatory, allergic and/or proliferative processes:
- nephrotic syndrome - all nephritides (vii) liver disorders associated with inflammatory, allergic and/or proliferative processes:
- acute liver cell necrosis - acute hepatitis of varying origin, e.g.
viral, toxic, drug-induced - chronic aggressive and/or chronic intermittent hepatitis (viii) gastrointestinal disorders associated with inflammatory, allergic and/or proliferative processes:
- regional enteritis (Crohn's disease) - ulcerative colitis - gastritis - reflux esophagitis - gastroenteritides of other origin, e.g.
indigenous sprue (ix) proctological disorders associated with inflammatory, allergic and/or proliferative processes:
- anal eczema - fissures - hemorrhoids - idiopathic proctitis (x) ocular disorders associated with inflammatory, allergic and/or proliferative processes:
- allergic keratitis, uveitis, iritis, - conjunctivitis - blepharitis - optic neuritis - chorioditis - sympathetic ophthalmia (xi) ear-nose-throat disorders associated with inflammatory, allergic and/or proliferative processes:
- allergic rhinitis, hayfever - otitis externa, e.g. caused by contact exema, infection etc.
- otitis media (xii) neurological disorders associated with inflammatory, allergic and/or proliferative processes:
- cerebral edema, especially tumor-related cerebral edema - multiple sclerosis - acute encephalomyelitis - meningitis - various types of seizures, e.g. infantile spasms (xiii) blood disorders associated with inflammatory, allergic and/or proliferative processes:
- acquired hemolytic anemia - idiopathic thrombocytopenia (xiv) neoplastic disorders associated with inflammatory, allergic and/or proliferative processes:
- acute lymphatic leukemia - malignant lymphomas - lymphogranulomatoses - lymphosarcomas - extensive metastases, especially associated with breast, bronchial and prostate carcinomas (xv) endocrine disorders associated with inflammatory, allergic and/or proliferative processes - endocrine orbitopathy - thyrotoxic crisis - de Quervain's thyroiditis - Hashimoto's thyroiditis - Basedow's disease (xvi) organ and tissue transplantations, graft-versus-hose disease (xvii) severe states of shock, e.g. anaphylactic shock, systemic inflammatory response syndrome (SIRS) (xviii) emesis associated with inflammatory, allergic and/or proliferative processes:
- e.g. in combination with a 5-HT3 antagonist in cytostic-related vomiting.
(xix) pain of inflammatory origin, e.g. lumbago (xx) replacement therapy for:
- congenital primary adrenal insufficiency, e.g. congenital adrenogenital syndrome - acquired primary adrenal insufficiency, e.g.
Addison's disease, autoimmune adrenalitis, post-infection, tumors, metastases etc.
- congenital secondary adrenal insufficiency, e.g. congenital hypopituitarism - acquired secondary adrenal insufficiency, e.g. post-infection, tumors etc.
Medicaments comprising stereoisomers of the general formula I show a particular efficacy for the following disorders:
1. lung disorders 2. rheumatic disorders/autoimmune diseases 3. dermatological disorders 4. degenerative joint disorders 5. vessel inflammations 6. graft versus host disease 7. severe states of shock 8. emesis associated with inflammatory, allergic and/or proliferative processes 9. inflammation-related pain.
In addition, the compounds of the invention of the general formula (I) can be employed for the therapy and prophylaxis of further pathological states which are not mentioned above but for which synthetic glucocorticoids are currently used (concerning this, see Hatz, HJ, Glucocorticoide: Immunologische Grundlagen, Pharmakologie und Therapierichtlinien, Wissenschafliche Verlagsgesellachaft mbH, Stuttgart, 1998).
All the aforementioned indications are described in detail in Hatz, HJ, Glucocorticoide: Immunologische Grundlagen, Pharmakologie und Therapierichtlinien, Wissenschafliche Verlagsgesellachaft mbH, Stuttgart, 1998).
The suitable dose for a therapeutic effect in the abovementioned pathological states varies and depends for example on the potency of the compound of the general formula (I), the patient (e.g. height, weight, gender, etc.), the mode of administration and the nature and severity of the conditions to be treated, and the use as prophylactic or therapeutic agent.
The invention relates to the use of the claimed compounds for manufacturing a pharmaceutical composition.
The invention further provides:
(i) the use of one of the compounds of the invention of the general formula (I) or mixture thereof for manufacturing a pharmaceutical composition for the treatment or prevention of inflammatory processes, and especially for the treatment of a DISORDER (as defined above);
- allergic rhinitis, hayfever - otitis externa, e.g. caused by contact exema, infection etc.
- otitis media (xii) neurological disorders associated with inflammatory, allergic and/or proliferative processes:
- cerebral edema, especially tumor-related cerebral edema - multiple sclerosis - acute encephalomyelitis - meningitis - various types of seizures, e.g. infantile spasms (xiii) blood disorders associated with inflammatory, allergic and/or proliferative processes:
- acquired hemolytic anemia - idiopathic thrombocytopenia (xiv) neoplastic disorders associated with inflammatory, allergic and/or proliferative processes:
- acute lymphatic leukemia - malignant lymphomas - lymphogranulomatoses - lymphosarcomas - extensive metastases, especially associated with breast, bronchial and prostate carcinomas (xv) endocrine disorders associated with inflammatory, allergic and/or proliferative processes - endocrine orbitopathy - thyrotoxic crisis - de Quervain's thyroiditis - Hashimoto's thyroiditis - Basedow's disease (xvi) organ and tissue transplantations, graft-versus-hose disease (xvii) severe states of shock, e.g. anaphylactic shock, systemic inflammatory response syndrome (SIRS) (xviii) emesis associated with inflammatory, allergic and/or proliferative processes:
- e.g. in combination with a 5-HT3 antagonist in cytostic-related vomiting.
(xix) pain of inflammatory origin, e.g. lumbago (xx) replacement therapy for:
- congenital primary adrenal insufficiency, e.g. congenital adrenogenital syndrome - acquired primary adrenal insufficiency, e.g.
Addison's disease, autoimmune adrenalitis, post-infection, tumors, metastases etc.
- congenital secondary adrenal insufficiency, e.g. congenital hypopituitarism - acquired secondary adrenal insufficiency, e.g. post-infection, tumors etc.
Medicaments comprising stereoisomers of the general formula I show a particular efficacy for the following disorders:
1. lung disorders 2. rheumatic disorders/autoimmune diseases 3. dermatological disorders 4. degenerative joint disorders 5. vessel inflammations 6. graft versus host disease 7. severe states of shock 8. emesis associated with inflammatory, allergic and/or proliferative processes 9. inflammation-related pain.
In addition, the compounds of the invention of the general formula (I) can be employed for the therapy and prophylaxis of further pathological states which are not mentioned above but for which synthetic glucocorticoids are currently used (concerning this, see Hatz, HJ, Glucocorticoide: Immunologische Grundlagen, Pharmakologie und Therapierichtlinien, Wissenschafliche Verlagsgesellachaft mbH, Stuttgart, 1998).
All the aforementioned indications are described in detail in Hatz, HJ, Glucocorticoide: Immunologische Grundlagen, Pharmakologie und Therapierichtlinien, Wissenschafliche Verlagsgesellachaft mbH, Stuttgart, 1998).
The suitable dose for a therapeutic effect in the abovementioned pathological states varies and depends for example on the potency of the compound of the general formula (I), the patient (e.g. height, weight, gender, etc.), the mode of administration and the nature and severity of the conditions to be treated, and the use as prophylactic or therapeutic agent.
The invention relates to the use of the claimed compounds for manufacturing a pharmaceutical composition.
The invention further provides:
(i) the use of one of the compounds of the invention of the general formula (I) or mixture thereof for manufacturing a pharmaceutical composition for the treatment or prevention of inflammatory processes, and especially for the treatment of a DISORDER (as defined above);
(ii) a method for the treatment or prevention of inflammatory processes, especially for the treatment of a DISORDER (as defined above), which method includes administration of a pharmaceutically effective amount of a compound of the general formula (I), where the amount alleviates or suppresses the disease or the symptoms, and where the compound is given to a patient, preferably a mammal, in particular a human, requiring such a treatment;
(iii) a pharmaceutical composition having an antiinflammatory effect, in particular for the treatment of a DISORDER (as defined above), where the composition includes one of the compounds of the invention of the general formula (I) or mixtures thereof and, where appropriate, at least one pharmaceutical excipient and/or carrier.
Satisfactory results are generally to be expected in animals when the daily doses include a range from 1 pg to 100 000 pg of the compound of the invention per kg of body weight. For larger mammals, for example humans, a recommended daily dose is in the range from 1 pg to 100 000 pg per kg of body weight. A dose of 10 to 000 pg per kg of body weight is preferred, and a dose of 10 to 10 000 pg per kg of body weight is more preferred. This dose is for example expediently administered more than once a day. For the treatment of 30 acute shock (e.g. anaphylactic shock) it is possible to give single doses which are distinctly higher than the abovementioned doses.
The pharmaceutical products based on the novel compounds are formulated in a manner known per se by processing the active ingredient with the carrier substances, fillers, substances influencing disintegration, binders, humectants, lubricants, absorbents, diluents, masking flavors, colorants etc.
(iii) a pharmaceutical composition having an antiinflammatory effect, in particular for the treatment of a DISORDER (as defined above), where the composition includes one of the compounds of the invention of the general formula (I) or mixtures thereof and, where appropriate, at least one pharmaceutical excipient and/or carrier.
Satisfactory results are generally to be expected in animals when the daily doses include a range from 1 pg to 100 000 pg of the compound of the invention per kg of body weight. For larger mammals, for example humans, a recommended daily dose is in the range from 1 pg to 100 000 pg per kg of body weight. A dose of 10 to 000 pg per kg of body weight is preferred, and a dose of 10 to 10 000 pg per kg of body weight is more preferred. This dose is for example expediently administered more than once a day. For the treatment of 30 acute shock (e.g. anaphylactic shock) it is possible to give single doses which are distinctly higher than the abovementioned doses.
The pharmaceutical products based on the novel compounds are formulated in a manner known per se by processing the active ingredient with the carrier substances, fillers, substances influencing disintegration, binders, humectants, lubricants, absorbents, diluents, masking flavors, colorants etc.
which are in use in pharmaceutical technology, and converting into the desired administration form.
Reference should be made in this connection to Remington's Pharmaceutical Science, 15th ed. Mack Publishing Company, East Pennsylvania (1980).
Particularly suitable for oral administration are tablets, coated tablets, capsules, pills, powders, granules, pastilles, suspensions, emulsions or solutions.
Preparations for injection and infusion are possible for parenteral administration.
Appropriately prepared crystal suspensions can be used for intraarticular injection.
Aqueous and oily solutions for injections or suspensions and corresponding depot preparations can be used for intramuscular injection.
The novel compounds can be used for rectal administration in the form of suppositories, capsules, solutions (e.g. in the form of enemas) and ointments both for systemic and for local therapy.
The novel compounds can be used in the form of aerosols and inhalations for pulmonary administration thereof.
For local use on eyes, the external auditory canal, middle ear, nasal cavity and paranasal sinuses, the novel compounds can be used as drops, ointments, tinctures and gels in appropriate pharmaceutical preparations.
Formulations possible for topical application are gels, ointments, greasy ointments, creams, pastes, dusting powders, suspensions, emulsions and solutions. The dosage of the compounds of the general formula (I) in these preparations should be 0.01% - 20% in order to achieve an adequate pharmacological effect.
The invention likewise includes the compounds of the invention of the general formula (I) as therapeutic active ingredient. The invention further includes the compounds of the invention of the general formula (I) as therapeutic active ingredient together with one or more pharmaceutically suitable and acceptable excipients and/or carriers.
The compounds of the invention of the general formula (I) can also where appropriate be formulated and/or administered in combination with further active ingredients.
The invention therefore also relates to combination therapies or combined compositions in which a compounds of the general formula (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a compound of the general formula (I) or a pharmaceutically acceptable salt thereof, is administered either simultaneously (where appropriate in the same composition) or successively together with one or more medicaments for the treatment of one of the pathological states mentioned above. For the treatment of rheumatoid arthritis, osteoarthritis, COPD (chronic obstructive pulmonary disorder), asthma or allergic rhinitis, for example, it is possible to combine a compound of the general formula (I) of the present invention with one or more medicaments for the treatment of such a condition. Where such a combination is administered by inhalation, the medicament to be combined can be selected from the following list:
= a PDE4 inhibitor including an inhibitor of the PDE4D isoform;
Reference should be made in this connection to Remington's Pharmaceutical Science, 15th ed. Mack Publishing Company, East Pennsylvania (1980).
Particularly suitable for oral administration are tablets, coated tablets, capsules, pills, powders, granules, pastilles, suspensions, emulsions or solutions.
Preparations for injection and infusion are possible for parenteral administration.
Appropriately prepared crystal suspensions can be used for intraarticular injection.
Aqueous and oily solutions for injections or suspensions and corresponding depot preparations can be used for intramuscular injection.
The novel compounds can be used for rectal administration in the form of suppositories, capsules, solutions (e.g. in the form of enemas) and ointments both for systemic and for local therapy.
The novel compounds can be used in the form of aerosols and inhalations for pulmonary administration thereof.
For local use on eyes, the external auditory canal, middle ear, nasal cavity and paranasal sinuses, the novel compounds can be used as drops, ointments, tinctures and gels in appropriate pharmaceutical preparations.
Formulations possible for topical application are gels, ointments, greasy ointments, creams, pastes, dusting powders, suspensions, emulsions and solutions. The dosage of the compounds of the general formula (I) in these preparations should be 0.01% - 20% in order to achieve an adequate pharmacological effect.
The invention likewise includes the compounds of the invention of the general formula (I) as therapeutic active ingredient. The invention further includes the compounds of the invention of the general formula (I) as therapeutic active ingredient together with one or more pharmaceutically suitable and acceptable excipients and/or carriers.
The compounds of the invention of the general formula (I) can also where appropriate be formulated and/or administered in combination with further active ingredients.
The invention therefore also relates to combination therapies or combined compositions in which a compounds of the general formula (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a compound of the general formula (I) or a pharmaceutically acceptable salt thereof, is administered either simultaneously (where appropriate in the same composition) or successively together with one or more medicaments for the treatment of one of the pathological states mentioned above. For the treatment of rheumatoid arthritis, osteoarthritis, COPD (chronic obstructive pulmonary disorder), asthma or allergic rhinitis, for example, it is possible to combine a compound of the general formula (I) of the present invention with one or more medicaments for the treatment of such a condition. Where such a combination is administered by inhalation, the medicament to be combined can be selected from the following list:
= a PDE4 inhibitor including an inhibitor of the PDE4D isoform;
= a selective (3.sub2.adrenoceptor agonist such as, for example, metaproterenol, isoproterenol, isoprenaline, albuterol, salbutamol, formoterol, salmeterol, terbutaline, orciprenaline, bitolterol mesylate, pirbuterol or indacaterol;
= a muscarine receptor antagonist (for example an Ml, M2 or M3 antagonist, such as, for example, a selective M3 antagonist) such as, for example, ipratropium bromide, tiotropium bromide, oxitropium bromide, pirenzepine or telenzepine;
= a modulator of chemokine receptor function (such as, for example, a CCR1 receptor antagonist); or = an inhibitor of p38 kinase function.
For another aspect of the present invention, such a combination with a compound of the general formula (I) or a pharmaceutically acceptable salt thereof is employed for the treatment of COPD, asthma or allergic rhinitis and can be administered by inhalation or orally in combination with xanthine (such as, for example, aminophylline or theophylline), which can likewise be administered by inhalation or orally.
Examples The cis/trans nomenclature used in the examples below refers to the position of the substituents in position 1 and 2 of the saturated ring of the tetrahydronaphthalene system. In this connection, cis means that the highest priority substituent (according to the Cahn-Ingold-Prelog definition) on carbon atom 1 is located in the axial position and the highest priority substituent on carbon atom 2 is located in the equatorial position; or that the highest priority substituent (according to the Cahn-Ingold-Prelog definition) on carbon atom 1 is located in the equatorial position and the highest priority substituent on carbon atom 2 is located in the axial position. Correspondingly, trans means that the two highest priority substituents in each case on carbon atom 1 and carbon atom 2 are located either both in the axial position or both in the equatorial position.
Example 1: Synthesis of compounds of the general formula (III) 6-Fluoro-5-methoxy-4,4-dimethyl-2-trifluoromethyl-1,2,3,4-tetrahydronaphthalene-l,2-diol (cis and trans isomers) 1.75 g (5.67 mmol) of 4-(3-fluoro-2-methoxyphenyl)-2-hydroxy-4,4-dimethyl-2-trifluoromethylpentanal are dissolved in 20 ml of dichlormethane, and 2.6 ml of trifluoroacetic acid are added. The reaction is stirred at room temperature under a nitrogen atmosphere for 24 h. For workup, the reaction solution is evaporated with toluene in vacuo three times and then purified by chromatography: 1.28 g of cis-6-fluoro-5-methoxy-4,4-dimethyl-2-trifluoromethyl-1,2,3,4-tetrahydro-naphthalene-1,2-diol and 300 mg of trans-6-fluoro-5-methoxy-4,4-dimethyl-2-trifluoromethyl-1,2,3,4-tetrahydronaphthalene-1,2-diol (900).
cis-6-Fluoro-5-methoxy-4,4-dimethyl-2-trifluoromethyl-1,2,3,4-tetrahydronaphthalene-1,2-diol: 1H-NMR (300 MHz, CDC13) : b/ppm = 1. 45 (s, 3H) , l, 59 (s, 3H) , 1.81 (d, 1H) , 2.08 (d, 1H), 2.56 (d, 1H), 3.18 (d, 1H), 3.94 (d, 3H), 5.03 (d, 1H), 7.03 (dd, 1H), 7.31 (ddd, 1H).
trans-6-Fluoro-5-methoxy-4,4-dimethyl-2-trifluoro-methyl-1,2,3,4-tetrahydronaphthalene-1,2-diol: 1H-NMR
(300 MHz, CDC13): b/ppm = 1.52 (s, 3H), 1.55 (s, 3H), 1.83 (dd, 1H), 1.87-1.90 (m, 2H), 2.42 (d, 1H), 3.95 (d, 3H), 4.68 (dd, 1H), 6. 99-7 . 06 (m, 2H).
The following compounds are obtained in analogy to the above method:
= a muscarine receptor antagonist (for example an Ml, M2 or M3 antagonist, such as, for example, a selective M3 antagonist) such as, for example, ipratropium bromide, tiotropium bromide, oxitropium bromide, pirenzepine or telenzepine;
= a modulator of chemokine receptor function (such as, for example, a CCR1 receptor antagonist); or = an inhibitor of p38 kinase function.
For another aspect of the present invention, such a combination with a compound of the general formula (I) or a pharmaceutically acceptable salt thereof is employed for the treatment of COPD, asthma or allergic rhinitis and can be administered by inhalation or orally in combination with xanthine (such as, for example, aminophylline or theophylline), which can likewise be administered by inhalation or orally.
Examples The cis/trans nomenclature used in the examples below refers to the position of the substituents in position 1 and 2 of the saturated ring of the tetrahydronaphthalene system. In this connection, cis means that the highest priority substituent (according to the Cahn-Ingold-Prelog definition) on carbon atom 1 is located in the axial position and the highest priority substituent on carbon atom 2 is located in the equatorial position; or that the highest priority substituent (according to the Cahn-Ingold-Prelog definition) on carbon atom 1 is located in the equatorial position and the highest priority substituent on carbon atom 2 is located in the axial position. Correspondingly, trans means that the two highest priority substituents in each case on carbon atom 1 and carbon atom 2 are located either both in the axial position or both in the equatorial position.
Example 1: Synthesis of compounds of the general formula (III) 6-Fluoro-5-methoxy-4,4-dimethyl-2-trifluoromethyl-1,2,3,4-tetrahydronaphthalene-l,2-diol (cis and trans isomers) 1.75 g (5.67 mmol) of 4-(3-fluoro-2-methoxyphenyl)-2-hydroxy-4,4-dimethyl-2-trifluoromethylpentanal are dissolved in 20 ml of dichlormethane, and 2.6 ml of trifluoroacetic acid are added. The reaction is stirred at room temperature under a nitrogen atmosphere for 24 h. For workup, the reaction solution is evaporated with toluene in vacuo three times and then purified by chromatography: 1.28 g of cis-6-fluoro-5-methoxy-4,4-dimethyl-2-trifluoromethyl-1,2,3,4-tetrahydro-naphthalene-1,2-diol and 300 mg of trans-6-fluoro-5-methoxy-4,4-dimethyl-2-trifluoromethyl-1,2,3,4-tetrahydronaphthalene-1,2-diol (900).
cis-6-Fluoro-5-methoxy-4,4-dimethyl-2-trifluoromethyl-1,2,3,4-tetrahydronaphthalene-1,2-diol: 1H-NMR (300 MHz, CDC13) : b/ppm = 1. 45 (s, 3H) , l, 59 (s, 3H) , 1.81 (d, 1H) , 2.08 (d, 1H), 2.56 (d, 1H), 3.18 (d, 1H), 3.94 (d, 3H), 5.03 (d, 1H), 7.03 (dd, 1H), 7.31 (ddd, 1H).
trans-6-Fluoro-5-methoxy-4,4-dimethyl-2-trifluoro-methyl-1,2,3,4-tetrahydronaphthalene-1,2-diol: 1H-NMR
(300 MHz, CDC13): b/ppm = 1.52 (s, 3H), 1.55 (s, 3H), 1.83 (dd, 1H), 1.87-1.90 (m, 2H), 2.42 (d, 1H), 3.95 (d, 3H), 4.68 (dd, 1H), 6. 99-7 . 06 (m, 2H).
The following compounds are obtained in analogy to the above method:
6-Fluoro-5-methoxy-4,4-dimethyl-2-trifluoromethyl-1,2,3,4-tetrahydronaphthalene-1,2-diol (cis and trans isomer mixture) 7-Methoxy-4,4-dimethyl-2-trifluoromethyl-1,2,3,4-tetrahydronaphthalene-1,2-diol (cis and trans isomer mixture) Example 2: Synthesis of compounds of the general formula (IV):
Example 2A: cis-l-Amino-6-fluoro-5-methoxy-4,4-di-methyl-2-trifluoromethyl-1,2,3,4-tetrahydro-naphthalen-2-ol a) Benzyl 7-fluoro-6-methoxy-5,5-dimethyl-2,2-dioxo-3a-trifluoromethyl-3a,4,5,9b-tetrahydro-3-oxy-2lambda*6*-thia-l-aza-cyclopenta[a]naphthalene-l-carboxylate 2.00 g (6.48 mmol) of 6-fluoro-5-methoxy-4,4-dimethyl-2-trifluoromethyl-1,2,3,4-tetrahydronaphthalene-1,2-diol and 5.12 g (16.2 mmol) of Burgess's reagent are dissolved in 50 ml of THF and stirred under a nitrogen atmosphere at 65-70 C for 7 h and then at room temperature for 12 h. The reaction solution is evaporated in vacuo, and the residue is purified by chromatography: 1.66 g (51%).
1H-NMR (300 MHz, CDC13) : 6/ppm = 1. 54 (s, 3H) , 1.59 (s, 3H), 2.01 (d, 1H), 2.29 (d, 1H) , 3.95 (d, 3H), 5.36 (d, 1H) , 5.44 (d, 1H), 5.95 (s, 1H) , 6.97 (dd, 1H) , 7.19 (dd, 1H), 7.35-7.42 (m, 5H).
b) cis-l-Amino-6-fluoro-5-methoxy-4,4-dimethyl-2-tri-fluoromethyl-1,2,3,4-tetrahydronaphthalen-2-ol 1.2 g (2.38 mmol) of benzyl 7-fluoro-6-methoxy-5,5-dimethyl-2,2-dioxo-3a-trifluoromethyl-3a,4,5,9b-tetrahydro-3-oxy-2lambda*6*-thia-l-aza-cyclopenta[a]naphthalene-l-carboxylate are dissolved in 12 ml of dioxane and, after addition of 8 ml of 4N HC1 solution, treated in a microwave at 250 watt and 140 C
Example 2A: cis-l-Amino-6-fluoro-5-methoxy-4,4-di-methyl-2-trifluoromethyl-1,2,3,4-tetrahydro-naphthalen-2-ol a) Benzyl 7-fluoro-6-methoxy-5,5-dimethyl-2,2-dioxo-3a-trifluoromethyl-3a,4,5,9b-tetrahydro-3-oxy-2lambda*6*-thia-l-aza-cyclopenta[a]naphthalene-l-carboxylate 2.00 g (6.48 mmol) of 6-fluoro-5-methoxy-4,4-dimethyl-2-trifluoromethyl-1,2,3,4-tetrahydronaphthalene-1,2-diol and 5.12 g (16.2 mmol) of Burgess's reagent are dissolved in 50 ml of THF and stirred under a nitrogen atmosphere at 65-70 C for 7 h and then at room temperature for 12 h. The reaction solution is evaporated in vacuo, and the residue is purified by chromatography: 1.66 g (51%).
1H-NMR (300 MHz, CDC13) : 6/ppm = 1. 54 (s, 3H) , 1.59 (s, 3H), 2.01 (d, 1H), 2.29 (d, 1H) , 3.95 (d, 3H), 5.36 (d, 1H) , 5.44 (d, 1H), 5.95 (s, 1H) , 6.97 (dd, 1H) , 7.19 (dd, 1H), 7.35-7.42 (m, 5H).
b) cis-l-Amino-6-fluoro-5-methoxy-4,4-dimethyl-2-tri-fluoromethyl-1,2,3,4-tetrahydronaphthalen-2-ol 1.2 g (2.38 mmol) of benzyl 7-fluoro-6-methoxy-5,5-dimethyl-2,2-dioxo-3a-trifluoromethyl-3a,4,5,9b-tetrahydro-3-oxy-2lambda*6*-thia-l-aza-cyclopenta[a]naphthalene-l-carboxylate are dissolved in 12 ml of dioxane and, after addition of 8 ml of 4N HC1 solution, treated in a microwave at 250 watt and 140 C
for 20 minutes twice. For workup, the solution is evaporated in vacuo, and the residue is adjusted to pH 14 with 4N sodium hydroxide solution at 0 C and extracted three times with ethyl acetate. The combined organic phases are washed with saturated sodium chloride solution, dried over sodium sulfate, filtered and concentrated in vacuo: 41% of the desired product.
1H-NMR (300 MHz, CDC13) : b/ppm = 1.36 (s, 3H), 1.49 (s, 3H), 1.78 (s, 1H), 1.95 (d, 1H), 3.83 (d, 3H), 4.03 (s, 1H) , 7.12 (dd, 1H), 7.51 (dd, 1H).
Example 2B: trans-l-Amino-6-fluoro-5-methoxy-4,4-dimethyl-2-trifluoromethyl-1,2,3,4-tetrahydro-naphthalen-2-ol a) 1-Azido-6-fluoro-5-methoxy-4,4-dimethyl-2-trifluoro-methyl-1,2,3,4-tetrahydronaphthalen-2-ol 420 mg (1.27 mmol) of tetrabromomethane and 454 mg (1.14 mmol) of 1,2-bis(diphenylphoshino)ethane (DiPhos) are added to a solution of 130 mg (0.422 mmol) of 6-fluoro-5-methoxy-4,4-dimethyl-2-trifluoromethyl-1,2,3,4-tetrahydronaphthalene-l,2-cis-diol in 4.5 ml of dichlormethane at room temperature under a nitrogen atmosphere. It is possible analogously to start this reaction also with the corresponding 1,2-cis/trans-diol mixture instead of the 1,2-cis-diol. After stirring at room temperature for 3 h, 20 ml of ether are added and, after stirring for 5 min, the resulting precipitate is filtered off and washed with ether, and the solvent is evaporated in vacuo: 200 mg of crude product which is employed without further purification in the next reaction.
190 mg (0.512 mmol) of crude product are mixed with 2 ml of a sodium azide-containing DMSO solution (150 mg of sodium azide in 5 ml of dimethyl sulfoxide are stirred at room temperature for 24 h). The reaction solution is stirred at room temperature for 3 h and at 40-45 C for 3 h under a nitrogen atmosphere. For workup, 5 ml of water are added to the reaction mixture and it is extracted three times with ethyl acetate. The combined organic phases are washed with saturated sodium chloride solution, dried over sodium sulfate, filtered, concentrated in vacuo and purified by column chromatography: 80 mg of the title compound.
1H-NMR (300 MHz, CDC13) : 6/ppm = 1.52 (s, 3H), 1.56 (s, 3H), 1.84 (dd, 1H), 1.97 (s, 1H), 2.25 (d, 1H), 3.98 (d, 3H), 4.48 (d, 1H), 6.93 (dd, 1H), 7.07 (dd, 1H).
b) trans-l-Amino-6-fluoro-5-methoxy-4,4-dimethyl-2-trifluoromethyl-1,2,3,4-tetrahydronaphthalen-2-ol 311 mg (4.76 mmol) of zinc powder are added to a solution of 1.22 g (3.66 mmol) of l-azido-6-fluoro-5-methoxy-4,4-dimethyl-2-trifluoromethyl-1,2,3,4-tetrahydronaphthalen-2-ol and 450 mg (8.42 mmol) of ammonium chloride in 9.7 ml of ethanol and 3.3 ml of water, and the mixture is then stirred at 90 C under a nitrogen atmosphere for 30 min. After cooling to room temperature, 25 ml of ethyl acetate and 1.22 ml of ammonia solution are added, and the mixture is stirred for 5 min and filtered. The filtrate is washed with saturated sodium chloride solution, dried over sodium sulfate, filtered and concentrated in vacuo. The crude product is purified by column chromatography: 950 mg of the title compound.
1H-NMR (300 MHz, CDC13) : 6/ppm = 1. 42 (s, 3H) , 1.46 (s, 3H), 1.61 (dd, 1H), 1.77 (bs, 2H), 2.20 (d, 1H), 3.84 (d, 3H), 3.88 (s, 1H), 5.63 (s, 1H), 6.98 (dd, 1H), 7.10 (dd, 1H).
Example 3: Synthesis of compounds of the general formula (I) Example 3A: N-(cis-6-fluoro-2-hydroxy-5-methoxy-4,4-dimethyl-2-trifluoromethyl-1,2,3,4-tetrahydro-naphthalen-1-yl)naphthalene-2-carboxamide A solution of 4-dimethylaminopyridine (73 mg, 0.60 mmol) in DMF (0.4 ml) and a solution of 2-naphthalenecarbonyl chloride (84 mg, 0.44 mmol) in DMF (0.8 ml) are successively added to a solution of cis-l-amino-6-fluoro-5-methoxy-4,4-dimethyl-2-tri-fluoromethyl-1,2,3,4-tetrahydronaphthalen-2-ol (100 mg, 0.40 mmol) in DMF (0.8 ml), and the resulting mixture is stirred at room temperature overnight. For workup, sodium bicarbonate solution (3 ml, half-saturated solution in water) and ethyl acetate (6 ml) are added and, after extraction, the organic phase is isolated and concentrated. One third of the resulting crude product is purified by HPLC-MS and affords 28 mg of the title compound.
F
F
F
= OH F
HPLC: 3.4 min (method A).
MS (ESI) : m/z 461.
1H-NMR (CDC13, 400 MHz): 8/ppm = 1.52 (s, 3H), 1.67 (s, 3H), 2.12 (m, 2H), 3.30 (broad s), 3.97 (s br, 3H), 5.67 (d, 1H), 6.93-7.07 (m, 3H), 7.57 (m, 2H), 7.91 (m, 4H), 8.36 (s, 1H).
Example 3B: N-(cis-6-fluoro-2,5-dihydroxy-4,4-dimethyl-2-trifluoromethyl-1,2,3,4-tetrahydronaphthalen-1-yl)naphthalene-2-carboxamide The remaining two thirds of the crude product from the synthesis described above in example 3A are dissolved in dichloromethane (0.5 ml) and cooled to -40 C and, at this temperature, boron tribromide solution (1 ml, 1.OM
in dichloromethane, 1.0 mmol) is added, and the mixture is warmed to room temperature while stirring overnight.
1H-NMR (300 MHz, CDC13) : b/ppm = 1.36 (s, 3H), 1.49 (s, 3H), 1.78 (s, 1H), 1.95 (d, 1H), 3.83 (d, 3H), 4.03 (s, 1H) , 7.12 (dd, 1H), 7.51 (dd, 1H).
Example 2B: trans-l-Amino-6-fluoro-5-methoxy-4,4-dimethyl-2-trifluoromethyl-1,2,3,4-tetrahydro-naphthalen-2-ol a) 1-Azido-6-fluoro-5-methoxy-4,4-dimethyl-2-trifluoro-methyl-1,2,3,4-tetrahydronaphthalen-2-ol 420 mg (1.27 mmol) of tetrabromomethane and 454 mg (1.14 mmol) of 1,2-bis(diphenylphoshino)ethane (DiPhos) are added to a solution of 130 mg (0.422 mmol) of 6-fluoro-5-methoxy-4,4-dimethyl-2-trifluoromethyl-1,2,3,4-tetrahydronaphthalene-l,2-cis-diol in 4.5 ml of dichlormethane at room temperature under a nitrogen atmosphere. It is possible analogously to start this reaction also with the corresponding 1,2-cis/trans-diol mixture instead of the 1,2-cis-diol. After stirring at room temperature for 3 h, 20 ml of ether are added and, after stirring for 5 min, the resulting precipitate is filtered off and washed with ether, and the solvent is evaporated in vacuo: 200 mg of crude product which is employed without further purification in the next reaction.
190 mg (0.512 mmol) of crude product are mixed with 2 ml of a sodium azide-containing DMSO solution (150 mg of sodium azide in 5 ml of dimethyl sulfoxide are stirred at room temperature for 24 h). The reaction solution is stirred at room temperature for 3 h and at 40-45 C for 3 h under a nitrogen atmosphere. For workup, 5 ml of water are added to the reaction mixture and it is extracted three times with ethyl acetate. The combined organic phases are washed with saturated sodium chloride solution, dried over sodium sulfate, filtered, concentrated in vacuo and purified by column chromatography: 80 mg of the title compound.
1H-NMR (300 MHz, CDC13) : 6/ppm = 1.52 (s, 3H), 1.56 (s, 3H), 1.84 (dd, 1H), 1.97 (s, 1H), 2.25 (d, 1H), 3.98 (d, 3H), 4.48 (d, 1H), 6.93 (dd, 1H), 7.07 (dd, 1H).
b) trans-l-Amino-6-fluoro-5-methoxy-4,4-dimethyl-2-trifluoromethyl-1,2,3,4-tetrahydronaphthalen-2-ol 311 mg (4.76 mmol) of zinc powder are added to a solution of 1.22 g (3.66 mmol) of l-azido-6-fluoro-5-methoxy-4,4-dimethyl-2-trifluoromethyl-1,2,3,4-tetrahydronaphthalen-2-ol and 450 mg (8.42 mmol) of ammonium chloride in 9.7 ml of ethanol and 3.3 ml of water, and the mixture is then stirred at 90 C under a nitrogen atmosphere for 30 min. After cooling to room temperature, 25 ml of ethyl acetate and 1.22 ml of ammonia solution are added, and the mixture is stirred for 5 min and filtered. The filtrate is washed with saturated sodium chloride solution, dried over sodium sulfate, filtered and concentrated in vacuo. The crude product is purified by column chromatography: 950 mg of the title compound.
1H-NMR (300 MHz, CDC13) : 6/ppm = 1. 42 (s, 3H) , 1.46 (s, 3H), 1.61 (dd, 1H), 1.77 (bs, 2H), 2.20 (d, 1H), 3.84 (d, 3H), 3.88 (s, 1H), 5.63 (s, 1H), 6.98 (dd, 1H), 7.10 (dd, 1H).
Example 3: Synthesis of compounds of the general formula (I) Example 3A: N-(cis-6-fluoro-2-hydroxy-5-methoxy-4,4-dimethyl-2-trifluoromethyl-1,2,3,4-tetrahydro-naphthalen-1-yl)naphthalene-2-carboxamide A solution of 4-dimethylaminopyridine (73 mg, 0.60 mmol) in DMF (0.4 ml) and a solution of 2-naphthalenecarbonyl chloride (84 mg, 0.44 mmol) in DMF (0.8 ml) are successively added to a solution of cis-l-amino-6-fluoro-5-methoxy-4,4-dimethyl-2-tri-fluoromethyl-1,2,3,4-tetrahydronaphthalen-2-ol (100 mg, 0.40 mmol) in DMF (0.8 ml), and the resulting mixture is stirred at room temperature overnight. For workup, sodium bicarbonate solution (3 ml, half-saturated solution in water) and ethyl acetate (6 ml) are added and, after extraction, the organic phase is isolated and concentrated. One third of the resulting crude product is purified by HPLC-MS and affords 28 mg of the title compound.
F
F
F
= OH F
HPLC: 3.4 min (method A).
MS (ESI) : m/z 461.
1H-NMR (CDC13, 400 MHz): 8/ppm = 1.52 (s, 3H), 1.67 (s, 3H), 2.12 (m, 2H), 3.30 (broad s), 3.97 (s br, 3H), 5.67 (d, 1H), 6.93-7.07 (m, 3H), 7.57 (m, 2H), 7.91 (m, 4H), 8.36 (s, 1H).
Example 3B: N-(cis-6-fluoro-2,5-dihydroxy-4,4-dimethyl-2-trifluoromethyl-1,2,3,4-tetrahydronaphthalen-1-yl)naphthalene-2-carboxamide The remaining two thirds of the crude product from the synthesis described above in example 3A are dissolved in dichloromethane (0.5 ml) and cooled to -40 C and, at this temperature, boron tribromide solution (1 ml, 1.OM
in dichloromethane, 1.0 mmol) is added, and the mixture is warmed to room temperature while stirring overnight.
For workup, potassium carbonate solution (1.5 ml, half-saturated solution in water) is added in an ice bath, the resulting mixture is stirred in the ice bath for 15 min and diluted and extracted with ethyl acetate (3 ml), and the organic phase is isolated and concentrated. The residue is purified by HPLC-MS and affords 88 mg of the title compound.
OH
F
F
F
= OH F
HPLC: 3.1 min (method A).
MS (ESI) : m/z 447.
1H-NMR (CDC13, 400 MHz) : b/ppm = 1. 56 (s, 3H) , 1. 69 (s, 3H), 2.13 (s, 2H), 5.43 (d, 1H), 5.66 (d, 1H), 6.88-7.03 (m, 3H), 7.57 (m, 2H), 7.92 (m, 4H), 8.37 (s, 1H).
The following compounds of the general formula (I) were obtained in analogy to examples 3A and 3B described above:
OH
F
F
F
= OH F
HPLC: 3.1 min (method A).
MS (ESI) : m/z 447.
1H-NMR (CDC13, 400 MHz) : b/ppm = 1. 56 (s, 3H) , 1. 69 (s, 3H), 2.13 (s, 2H), 5.43 (d, 1H), 5.66 (d, 1H), 6.88-7.03 (m, 3H), 7.57 (m, 2H), 7.92 (m, 4H), 8.37 (s, 1H).
The following compounds of the general formula (I) were obtained in analogy to examples 3A and 3B described above:
Ex. Structure Name MS HPLC
(ESI) 3C o N-(cis-6-fluoro-2- 461 3.3 min.
F F hydroxy-5-methoxy-4,4-(method A) F dimethyl-2-trifluoro-OH F
o NH methyl-1,2,3,4-tetrahydronaphthalen-~
1-yl)naphthalene-l-carboxamide 3D o N-(cis-6-fluoro-2- 463 2.9 min.
F
F hydroxy-5-methoxy-4,4- (method A) dimethyl-2-trifluoro-OH F
o NH methyl-1,2,3,4-tetrahydronaphthalen-I 1-yl)quinoxaline-6-N
N carboxamide 3E 1-cis-6-fluoro-2- 476 3.4 min.
F
F hydroxy-5-methoxy-4,4- (method A) oH F dimethyl-2-trifluoro-y methyl-1,2,3,4-/ NH
tetrahydronaphthalen-~ 1-yl)-3-naphthalen-2-ylurea 3F 0 1-(cis-6-fluoro-2- 476 3.3 min.
F
F hydroxy-5-methoxy-4,4- (method A) dimethyl-2-trifluoro-= OH F
oyNH methyl-1, 2, 3, 4-NH tetrahydronaphthalen-~ I 1-yl)-3-naphthalen-l-~ ylurea 3G o N-(cis-6-fluoro-2- 451 3.2 min.
F F hydroxy-5-methoxy-4,4-(method A) F dimethyl-2-trifluoro-OH F
O NH methyl-1,2,3,4-tetrahydronaphthalen-1-yl)benzofuran-5-carboxamide 3H o N-(cis-6-fluoro-2- 451 3.3 min.
F F hydroxy-5-methoxy-4,4-(method A) F dimethyl-2-trifluoro-OH F
O NH methyl-1,2,3,4-tetrahydronaphthalen-O
1-yl)benzofuran-2-\ carboxamide 31 N-(cis-6-fluoro-2- 498 3.5 min.
F hydroxy-5-methoxy-4,4- (method A) dimethyl-2-trifluoro-01~s~NH methyl-1, 2, 3, 4-tetrahydronaphthalen-I 1-yl)naphthalene-2-~ sulfonamide 3J o N-(cis-6-fluoro-2- 498 3.5 min.
F hydroxy-5-methoxy-4,4-156___~F (method A) F dimethyl-2-trifluoro-O\~ NHOH F methyl-1, 2, 3, 4-0=s tetrahydronaphthalen-I \ 1-yl)naphthalene-l-/
sulfonamide OH
3K F N-(cis-6-fluoro-2,5- 448 11.2 min.
F
dihydroxy-4,4- (method C) dimethyl-2-trifluoro-OH F
o NH methyl-1,2,3,4-~ tetrahydronaphthalen-I 1-yl)naphthalene-l-carboxamide OH
3L F N-(cis-6-fluoro-2,5- 438 10.3 min.
F dihydroxy-4,4- (method C) F
= OH F dimethyl-2-trifluoro-O NH
methyl-1,2,3,4-tetrahydronaphthalen-I 1-yl)benzofuran-5-o carboxamide 3M N-(cis-6-fluoro-2,5- 438 10.8 min.
dihydroxy-4,4- (method C) o dimethyl-2-trifluoro-0 MH methyl-1,2,3,4-OH ~
= L tetrahydronaphthalen-L
/ L 1-yl)benzofuran-2-OH carboxamide OH
3N F N-(cis-6-fluoro-2,5- 483 3.2 min.
F
dihydroxy-4,4- (method A) OH F dimethyl-2-trifluoro-O~\SNH methyl-1, 2, 3, 4-I ~ tetrahydronaphthalen-/ 1-yl)naphthalene-l-sulfonamide OH
30 F 1-(cis-6-fluoro-2,5- 463 10.7 min.
FF dihydroxy-4,4- (method C) = OH F dimethyl-2-OyNH
trifluoromethyl-NH
1,2,3,4-tetrahydro-naphthalen-l-yl)-3-naphthalen-l-ylurea OH
3P N-(cis-6-fluoro-2,5- 483 3.2 min.
F dihydroxy-4,4- (method A) 0 OH F dimethyl-2-trifluoro-\ ~NH
0=S
methyl-1,2,3,4-~ tetrahydronaphthalen-1-yl)naphthalene-2-sulfonamide OH
3Q F N-(cis-6-fluoro-2,5- 450 8.3 min.
F
F dihydroxy-4,4- (method C) = OH F dimethyl-2-trifluoro-O NH
methyl-1,2,3,4-I tetrahydronaphthalen-NI 1-yl)quinoxaline-6-carboxamide OH
3R 1-(cis-6-fluoro-2,5- 463 9.5 min.
FF dihydroxy-4,4- (method B) O NHOH F dimethyl-2-trifluoromethyl-/ trifluoromethyl-NH
~ 1,2,3,4-tetrahydro-~
naphthalen-l-yl)-3-naphthalen-2-ylurea OH
3S F N-(trans-6-fluoro-2,5- 447 2.9 min.
~
/ FF dihydroxy-4,4- (method A) oH F dimethyl-2-trifluoro-O NH
methyl-1,2,3,4-~ tetrahydronaphthalen-1-yl)naphthalene-2-carboxamide OH
3T F N-(trans-6-fluoro-2,5- 448 8.8 min.
\ F dihydroxy-4,4- (method B) /
oH F dimethyl-2-trifluoro-O NH
methyl-1,2,3,4-I tetrahydronaphthalen-/ 1-yl)naphthalene-l-carboxamide OH
3U F N-(trans-6-fluoro-2,5- 437 2.8 min.
FF dihydroxy-4,4- (method A) 1 6 o O H F dimethyl-2-trifluoro-NH methyl-1,2,3,4-tetrahydronaphthalen-0 1-yl)benzofuran-5-carboxamide OH
3V F N-(trans-6-fluoro-2,5- 438 3.0 min.
/ FF dihydroxy-4,4- (method A) 0 NHOH F dimethyl-2-trifluoro-methyl-1,2,3,4-o tetrahydronaphthalen-\ ~ 1-yl)benzofuran-2-carboxamide OH
3W F 1-(trans-6-fluoro-2,5- 463 9.2 min.
F dihydroxy-4,4- (method B) Oy NHOH F dimethyl-2-/ NH trifluoromethyl-~ 1,2,3,4-tetrahydro-naphthalen-1-yl)-3-naphthalen-2-ylurea OH
3X F 1-(trans-6-fluoro-2,5- 463 8.9 min.
F
F dihydroxy-4,4- (method B) 0~ NHOH F dimethyl-2-NH trifluoromethyl-~ 1,2,3,4-tetrahydro-~ naphthalen-l-yl)-3-naphthalen-1-ylurea 3Y \ N-(trans-6-fluoro-2- 462 2.8 min.
F
F hydroxy-5-methoxy-4,4- (method D) oH F dimethyl-2-trifluoro-O NH
methyl-1,2,3,4-I tetrahydronaphthalen-/ / 1-yl)naphthalene-l-carboxamide 3Z 1-(trans-6-fluoro-2- 476 3.1 min.
F hydroxy-5-methoxy-4,4- (method A) / = F
OH dimethyl-2-F
oyNH trifluoromethyl-NH 1,2,3,4-tetrahydro-~ naphthalen-1-yl)-3-~ I naphthalen-1-ylurea Example 4: Synthesis of further compounds of the general formula (I) Example 4: 6-Fluoro-5-methoxy-4,4-dimethyl-l-[(pyrazolo[1,5-a]pyridin-3ylmethyl)amino]-2-trifluoromethyl-1,2,3,4-tetrahydronaphthalen-2-ol, (cis isomer) ~O
F F F
F
OH
NH
C ~
N-N
cis-l-Amino-6-fluoro-5-methoxy-4,4-dimethyl-2-trifluoromethyl-1,2,3,4-tetrahydronaphthalen-2-ol (62 mg, 0.20 mmol) and pyrazolo[1,5-a]pyridine-3-carbaldehyde (30 mg (0.20 mmol) are dissolved in xylene (5.0 ml) and, after addition of titanium tetraethoxide (0.085 ml, 0.40 mmol), stirred at 150 C for 3 hours. After removal of the solvent, the residue is taken up in methanol (1.0 ml) and tetrahydrofuran (1.0 ml), and sodium borohydride (22 mg, 0.58 mmol) is added. The reaction is stopped after 3 hours at room temperature by adding water. Methanol and tetrahydrofuran are removed in vacuo. The aqueous phase is extracted with dichloromethane, and the organic phase is dried over sodium sulfate. Removal of the solvent and subsequent purification by chromatography (silica gel, hexane/ethyl acetate 3:7) result in 26 mg of the title compound.
1H-NMR (300 MHz, d6-DMSO): 6/ppm = 1.39 (s, 3H), 1.46 (s, 3H), 1.85 (d, 1H), 2.07 (d, 1H), 3.83 (d, 3H), 3.94 (s, 1H), 3.98 (d, 1H), 4.06 (d, 1H), 5.92 (br, 1H), 6.85 (td, 1H), 7.07-7.23 (m, 3H), 7.63 (d, 1H), 7.98 (s, 1H) , 8. 62 (d, 1H) Description of the HPLC methods Method A:
Waters Alliance 2795, Waters Photo Diode Array 2996 (200-320 nm), Micromass ZQ; column Micra NPS ODS 2 (33x4.6 mm, 1.5 um); gradient 0-90% acetonitrile (0.010 formic acid) in water (0.01% formic acid) (4.5 min.), 90% acetonitrile (0.01% formic acid) in water (0.01%
formic acid) (2 min); flow rate 0.8 ml/min.
Method B:
Waters Pump 515, Waters Dual Absorbance Detector 2487 (254 nm), Micromass ZQ; column X-Terra (150x4.6 mm, 5 pm); gradient 54-95% acetonitrile (0.01% formic acid) in water (0.01% formic acid) (10 min); flow rate 1 ml/min.
Method C:
Waters Pump 616, Hitachi L-4000 (254 nm); column Chromasil C8 (150x4.6 mm, 5 pm); gradient 30-95%
acetonitrile (0.01% formic acid) in water (0.01% formic acid) (15 min.), 95% acetonitrile (0.01% formic acid) in water (0.01% formic acid) (15 min); flow rate 1 ml/min.
Method D:
Hewlett-Packard 1100 Pump, HP1100 Detector (200-320 nm), Micromass PLCZ; column Micra NPS ODS 2 (33x4.6 mm, 1.5 pm); gradient 0-90% acetonitrile (0.01% trifluoro-acetic acid) in water (0.01% trifluoroacetic acid) (4.5 min), 90% acetonitrile (0.01% trifluoroacetic acid) in water (0.01% trifluoroacetic acid) (2 min);
flow rate 0.8 ml/min.
(ESI) 3C o N-(cis-6-fluoro-2- 461 3.3 min.
F F hydroxy-5-methoxy-4,4-(method A) F dimethyl-2-trifluoro-OH F
o NH methyl-1,2,3,4-tetrahydronaphthalen-~
1-yl)naphthalene-l-carboxamide 3D o N-(cis-6-fluoro-2- 463 2.9 min.
F
F hydroxy-5-methoxy-4,4- (method A) dimethyl-2-trifluoro-OH F
o NH methyl-1,2,3,4-tetrahydronaphthalen-I 1-yl)quinoxaline-6-N
N carboxamide 3E 1-cis-6-fluoro-2- 476 3.4 min.
F
F hydroxy-5-methoxy-4,4- (method A) oH F dimethyl-2-trifluoro-y methyl-1,2,3,4-/ NH
tetrahydronaphthalen-~ 1-yl)-3-naphthalen-2-ylurea 3F 0 1-(cis-6-fluoro-2- 476 3.3 min.
F
F hydroxy-5-methoxy-4,4- (method A) dimethyl-2-trifluoro-= OH F
oyNH methyl-1, 2, 3, 4-NH tetrahydronaphthalen-~ I 1-yl)-3-naphthalen-l-~ ylurea 3G o N-(cis-6-fluoro-2- 451 3.2 min.
F F hydroxy-5-methoxy-4,4-(method A) F dimethyl-2-trifluoro-OH F
O NH methyl-1,2,3,4-tetrahydronaphthalen-1-yl)benzofuran-5-carboxamide 3H o N-(cis-6-fluoro-2- 451 3.3 min.
F F hydroxy-5-methoxy-4,4-(method A) F dimethyl-2-trifluoro-OH F
O NH methyl-1,2,3,4-tetrahydronaphthalen-O
1-yl)benzofuran-2-\ carboxamide 31 N-(cis-6-fluoro-2- 498 3.5 min.
F hydroxy-5-methoxy-4,4- (method A) dimethyl-2-trifluoro-01~s~NH methyl-1, 2, 3, 4-tetrahydronaphthalen-I 1-yl)naphthalene-2-~ sulfonamide 3J o N-(cis-6-fluoro-2- 498 3.5 min.
F hydroxy-5-methoxy-4,4-156___~F (method A) F dimethyl-2-trifluoro-O\~ NHOH F methyl-1, 2, 3, 4-0=s tetrahydronaphthalen-I \ 1-yl)naphthalene-l-/
sulfonamide OH
3K F N-(cis-6-fluoro-2,5- 448 11.2 min.
F
dihydroxy-4,4- (method C) dimethyl-2-trifluoro-OH F
o NH methyl-1,2,3,4-~ tetrahydronaphthalen-I 1-yl)naphthalene-l-carboxamide OH
3L F N-(cis-6-fluoro-2,5- 438 10.3 min.
F dihydroxy-4,4- (method C) F
= OH F dimethyl-2-trifluoro-O NH
methyl-1,2,3,4-tetrahydronaphthalen-I 1-yl)benzofuran-5-o carboxamide 3M N-(cis-6-fluoro-2,5- 438 10.8 min.
dihydroxy-4,4- (method C) o dimethyl-2-trifluoro-0 MH methyl-1,2,3,4-OH ~
= L tetrahydronaphthalen-L
/ L 1-yl)benzofuran-2-OH carboxamide OH
3N F N-(cis-6-fluoro-2,5- 483 3.2 min.
F
dihydroxy-4,4- (method A) OH F dimethyl-2-trifluoro-O~\SNH methyl-1, 2, 3, 4-I ~ tetrahydronaphthalen-/ 1-yl)naphthalene-l-sulfonamide OH
30 F 1-(cis-6-fluoro-2,5- 463 10.7 min.
FF dihydroxy-4,4- (method C) = OH F dimethyl-2-OyNH
trifluoromethyl-NH
1,2,3,4-tetrahydro-naphthalen-l-yl)-3-naphthalen-l-ylurea OH
3P N-(cis-6-fluoro-2,5- 483 3.2 min.
F dihydroxy-4,4- (method A) 0 OH F dimethyl-2-trifluoro-\ ~NH
0=S
methyl-1,2,3,4-~ tetrahydronaphthalen-1-yl)naphthalene-2-sulfonamide OH
3Q F N-(cis-6-fluoro-2,5- 450 8.3 min.
F
F dihydroxy-4,4- (method C) = OH F dimethyl-2-trifluoro-O NH
methyl-1,2,3,4-I tetrahydronaphthalen-NI 1-yl)quinoxaline-6-carboxamide OH
3R 1-(cis-6-fluoro-2,5- 463 9.5 min.
FF dihydroxy-4,4- (method B) O NHOH F dimethyl-2-trifluoromethyl-/ trifluoromethyl-NH
~ 1,2,3,4-tetrahydro-~
naphthalen-l-yl)-3-naphthalen-2-ylurea OH
3S F N-(trans-6-fluoro-2,5- 447 2.9 min.
~
/ FF dihydroxy-4,4- (method A) oH F dimethyl-2-trifluoro-O NH
methyl-1,2,3,4-~ tetrahydronaphthalen-1-yl)naphthalene-2-carboxamide OH
3T F N-(trans-6-fluoro-2,5- 448 8.8 min.
\ F dihydroxy-4,4- (method B) /
oH F dimethyl-2-trifluoro-O NH
methyl-1,2,3,4-I tetrahydronaphthalen-/ 1-yl)naphthalene-l-carboxamide OH
3U F N-(trans-6-fluoro-2,5- 437 2.8 min.
FF dihydroxy-4,4- (method A) 1 6 o O H F dimethyl-2-trifluoro-NH methyl-1,2,3,4-tetrahydronaphthalen-0 1-yl)benzofuran-5-carboxamide OH
3V F N-(trans-6-fluoro-2,5- 438 3.0 min.
/ FF dihydroxy-4,4- (method A) 0 NHOH F dimethyl-2-trifluoro-methyl-1,2,3,4-o tetrahydronaphthalen-\ ~ 1-yl)benzofuran-2-carboxamide OH
3W F 1-(trans-6-fluoro-2,5- 463 9.2 min.
F dihydroxy-4,4- (method B) Oy NHOH F dimethyl-2-/ NH trifluoromethyl-~ 1,2,3,4-tetrahydro-naphthalen-1-yl)-3-naphthalen-2-ylurea OH
3X F 1-(trans-6-fluoro-2,5- 463 8.9 min.
F
F dihydroxy-4,4- (method B) 0~ NHOH F dimethyl-2-NH trifluoromethyl-~ 1,2,3,4-tetrahydro-~ naphthalen-l-yl)-3-naphthalen-1-ylurea 3Y \ N-(trans-6-fluoro-2- 462 2.8 min.
F
F hydroxy-5-methoxy-4,4- (method D) oH F dimethyl-2-trifluoro-O NH
methyl-1,2,3,4-I tetrahydronaphthalen-/ / 1-yl)naphthalene-l-carboxamide 3Z 1-(trans-6-fluoro-2- 476 3.1 min.
F hydroxy-5-methoxy-4,4- (method A) / = F
OH dimethyl-2-F
oyNH trifluoromethyl-NH 1,2,3,4-tetrahydro-~ naphthalen-1-yl)-3-~ I naphthalen-1-ylurea Example 4: Synthesis of further compounds of the general formula (I) Example 4: 6-Fluoro-5-methoxy-4,4-dimethyl-l-[(pyrazolo[1,5-a]pyridin-3ylmethyl)amino]-2-trifluoromethyl-1,2,3,4-tetrahydronaphthalen-2-ol, (cis isomer) ~O
F F F
F
OH
NH
C ~
N-N
cis-l-Amino-6-fluoro-5-methoxy-4,4-dimethyl-2-trifluoromethyl-1,2,3,4-tetrahydronaphthalen-2-ol (62 mg, 0.20 mmol) and pyrazolo[1,5-a]pyridine-3-carbaldehyde (30 mg (0.20 mmol) are dissolved in xylene (5.0 ml) and, after addition of titanium tetraethoxide (0.085 ml, 0.40 mmol), stirred at 150 C for 3 hours. After removal of the solvent, the residue is taken up in methanol (1.0 ml) and tetrahydrofuran (1.0 ml), and sodium borohydride (22 mg, 0.58 mmol) is added. The reaction is stopped after 3 hours at room temperature by adding water. Methanol and tetrahydrofuran are removed in vacuo. The aqueous phase is extracted with dichloromethane, and the organic phase is dried over sodium sulfate. Removal of the solvent and subsequent purification by chromatography (silica gel, hexane/ethyl acetate 3:7) result in 26 mg of the title compound.
1H-NMR (300 MHz, d6-DMSO): 6/ppm = 1.39 (s, 3H), 1.46 (s, 3H), 1.85 (d, 1H), 2.07 (d, 1H), 3.83 (d, 3H), 3.94 (s, 1H), 3.98 (d, 1H), 4.06 (d, 1H), 5.92 (br, 1H), 6.85 (td, 1H), 7.07-7.23 (m, 3H), 7.63 (d, 1H), 7.98 (s, 1H) , 8. 62 (d, 1H) Description of the HPLC methods Method A:
Waters Alliance 2795, Waters Photo Diode Array 2996 (200-320 nm), Micromass ZQ; column Micra NPS ODS 2 (33x4.6 mm, 1.5 um); gradient 0-90% acetonitrile (0.010 formic acid) in water (0.01% formic acid) (4.5 min.), 90% acetonitrile (0.01% formic acid) in water (0.01%
formic acid) (2 min); flow rate 0.8 ml/min.
Method B:
Waters Pump 515, Waters Dual Absorbance Detector 2487 (254 nm), Micromass ZQ; column X-Terra (150x4.6 mm, 5 pm); gradient 54-95% acetonitrile (0.01% formic acid) in water (0.01% formic acid) (10 min); flow rate 1 ml/min.
Method C:
Waters Pump 616, Hitachi L-4000 (254 nm); column Chromasil C8 (150x4.6 mm, 5 pm); gradient 30-95%
acetonitrile (0.01% formic acid) in water (0.01% formic acid) (15 min.), 95% acetonitrile (0.01% formic acid) in water (0.01% formic acid) (15 min); flow rate 1 ml/min.
Method D:
Hewlett-Packard 1100 Pump, HP1100 Detector (200-320 nm), Micromass PLCZ; column Micra NPS ODS 2 (33x4.6 mm, 1.5 pm); gradient 0-90% acetonitrile (0.01% trifluoro-acetic acid) in water (0.01% trifluoroacetic acid) (4.5 min), 90% acetonitrile (0.01% trifluoroacetic acid) in water (0.01% trifluoroacetic acid) (2 min);
flow rate 0.8 ml/min.
Claims (17)
1. A compound of the general formula (I) in which R1 and R2 are independently of one another a hydrogen atom, a hydroxy group, a halogen atom, an optionally substituted (C1-C10)-alkyl group, a (C1-C10) -alkoxy group, a (C1-C10) -alkylthio group, a (C1-C5) -perfluoroalkyl group, a cyano group, a nitro group, or an -NR9R9a group, or R1 and R2 together form a group selected from the groups -O- (CH2) n-O-, -O- (CH2) n-CH2-, -O-CH=CH-, - (CH2) n+2-, -NH- (CH2) n+l-, -N (C1-C3-alkyl) - (CH2) n+1-and -NH-N=CH-, where n is 1 or 2, and the terminal oxygen atoms and/or carbon atoms and/or nitrogen atoms are linked to directly adjacent ring carbon atoms, R11 is a hydrogen atom, a hydroxy group, a halogen atom, a cyano group, an optionally substituted (C1-C10) -alkyl group, a (C1-C10) -alkoxy group, a (C1-C10) -alkylthio group, or a (C1-C5) -perfluoroalkyl group, R12 is a hydrogen atom, a hydroxy group, a halogen atom, a cyano group, an optionally substituted (C1-C10) -alkyl group, or a (C1-C10) -alkoxy group, R3 is a C1-C10-alkyl group which is optionally substituted by 1 to 3 hydroxy groups, 1 to 3 halogen atoms, and/or 1 to 3(C1-C5)-alkoxy groups, an optionally substituted (C3-C7) -cycloalkyl group, an optionally substituted heterocyclyl group, an optionally substituted aryl group, or a mono- or bicyclic heteroaryl group which is optionally substituted by one or more groups which are selected independently of one another from (C1-C5) -alkyl groups which themselves may optionally be substituted by 1 to 3 hydroxy or 1 to 3-COOR13 groups, (C1-C5) -alkoxy groups, halogen atoms, hydroxy groups, -NR9R9a groups, and exo methylene groups and optionally comprises 1 to 4 nitrogen atoms and/or 1 to 2 oxygen atoms and/or 1 to 2 sulfur atoms and/or 1 to 2 keto groups, this group being linked by any position to the group X and possibly being optionally hydrogenated at one or more positions, R4 is a hydroxy group, an -OR10 group or an -O (CO) R10 group, R5 is a (C1-C10) -alkyl group which is optionally partly or completely fluorinated, a (C3-C7) cycloalkyl group, a (C1-C8) alkyl-(C3-C7) cycloalkyl group, a (C2-C8) alkenyl-(C3-C7) cycloalkyl group, a heterocyclyl group, a (C1-C8) alkylheterocyclyl group, a (C2-C8) -alkenylheterocyclyl group, an aryl group, a (C1-C8) alkylaryl group, a(C2-C8) alkenylaryl group, a (C2-C8) -alkynylaryl group, a mono- or bicyclic heteroaryl group which is optionally substituted by 1 to 2 keto groups, 1 to
2 (C1-C5) -alkyl groups, 1 to 2 (C1-C5) -alkoxy groups, 1 to 3 halogen atoms, and/or 1 to 2 exo methylene groups and comprises 1 to 3 nitrogen atoms and/or 1 to 2 oxygen atoms and/or 1 to 2 sulfur atoms, a (C1-C8) alkylheteroaryl group, a (C2-C8) alkenylheteroaryl group, or a (C2-C8) alkynylheteroaryl group, this group being linked by any position to the tetrahydronaphthalene system and possibly being optionally hydrogenated at one or more positions, R6 is a hydrogen atom, a halogen atom, or an optionally substituted (C1-C10)alkyl group, R7 and R8 are independently of one another a hydrogen atom, a halogen atom, an optionally substituted (Cl-C10)-alkyl group, a cyano group, together a (C1-C10)-alkylidene group or together with the carbon atom of the tetrahydronaphthalene system an optionally substituted (C3-C6)-cyclalkyl ring;
or R6 and R7 together form a fused five- to eight-membered saturated or unsaturated carbocycle or heterocycle which is optionally substituted by 1 to 2 keto groups, 1 to 2 (Cl-C5) -alkyl groups, 1 to 2 (C1-C5)-alkoxy groups, and/or 1 to 4 halogen atoms;
or R1 and R8 together form a fused five- to eight-membered saturated or unsaturated carbocycle or heterocycle which is optionally substituted by 1 to 2 keto groups, 1 to 2(C1-C5)-alkyl groups, 1 to 2 (C1-C5)-alkoxy groups, and/or 1 to 4 halogen atoms;
R9 and R9a are independently of one another a hydrogen atom, (C1-C5) -alkyl or - (CO) - (C1-C5) -alkyl, R10 is a(C1-C10) -alkyl group or any hydroxy protective group, R13 is a hydrogen atom or a(C1-C5) -alkyl group, and X is a group -C(=O)-, -C(=S)-, -C(=O)-NH-, -C(=S)-NH-, -S(0)m (where m = 1 or 2), -C(=O)-0-, -C (=S) -0- or a group -(CH2) p- (where p = 1, 2 or
or R6 and R7 together form a fused five- to eight-membered saturated or unsaturated carbocycle or heterocycle which is optionally substituted by 1 to 2 keto groups, 1 to 2 (Cl-C5) -alkyl groups, 1 to 2 (C1-C5)-alkoxy groups, and/or 1 to 4 halogen atoms;
or R1 and R8 together form a fused five- to eight-membered saturated or unsaturated carbocycle or heterocycle which is optionally substituted by 1 to 2 keto groups, 1 to 2(C1-C5)-alkyl groups, 1 to 2 (C1-C5)-alkoxy groups, and/or 1 to 4 halogen atoms;
R9 and R9a are independently of one another a hydrogen atom, (C1-C5) -alkyl or - (CO) - (C1-C5) -alkyl, R10 is a(C1-C10) -alkyl group or any hydroxy protective group, R13 is a hydrogen atom or a(C1-C5) -alkyl group, and X is a group -C(=O)-, -C(=S)-, -C(=O)-NH-, -C(=S)-NH-, -S(0)m (where m = 1 or 2), -C(=O)-0-, -C (=S) -0- or a group -(CH2) p- (where p = 1, 2 or
3), where if X comprises a carbonyl or thiocarbonyl function, this function is linked to the group -NH- in the general formula (I), with the proviso that if R3 is an optionally substituted (C1-C10) -alkyl group, X cannot be a -(CH2) p- group;
in the form of any stereoisomer or of a mixture of stereoisomers; or as pharmacologically acceptable salt or derivative.
2. A compound as claimed in claim 1, where X is a group -C(=O)-, -C(=O)-NH-, -SO2- or -CH2-.
3. A compound as claimed in claim 1 or 2, where R4 is a hydroxy group or a group -OR10
in the form of any stereoisomer or of a mixture of stereoisomers; or as pharmacologically acceptable salt or derivative.
2. A compound as claimed in claim 1, where X is a group -C(=O)-, -C(=O)-NH-, -SO2- or -CH2-.
3. A compound as claimed in claim 1 or 2, where R4 is a hydroxy group or a group -OR10
4. A compound as claimed in any of the preceding claims, where R5 is a (C1-C10) -alkyl group which is optionally partly or completely fluorinated.
5. A compound as claimed in any of the preceding claims, where R7 and R8 are each a methyl group, or together with the carbon atom of the tetrahydronaphthalene system form a cyclopropyl group.
6. A compound as claimed in any of the preceding claims, where R3 is an optionally substituted aryl or heteroaryl group.
7. A compound as claimed in claim 6, where the optionally substituted aryl or heteroaryl group is selected from the group consisting of naphthyl, benzofuranyl, pyrazolo[1,5-a]pyridinyl, phenyl, phthalidyl, isoindolyl, dihydroindolyl, dihydro-isoindolyl, dihydroisoquinolinyl, thiophthalidyl, benz-oxazinonyl, phthalazinonyl, quinolinyl, isoquinolinyl, quinolonyl, isoquinolonyl, indazolyl, benzothiazolyl, quinazolinyl, quinoxalinyl, cinnolinyl, phthalazinyl, 1,7- or 1,8-naphthyridinyl, dihydroindolonyl, dihydro-isoindolonyl, chromanyl, isochromanyl, benzimidazole or indolyl group.
8. A compound as claimed in any of the preceding claims for manufacturing a medicament.
9. The use of a compound as claimed in any of claims 1 to 7 for manufacturing a pharmaceutical composition for the treatment or prevention of inflammatory processes.
10. A method for the treatment or prevention of inflammatory processes in a patient, characterized in that a pharmaceutically effective amount of a compound of the general formula (I) as claimed in any of claims 1 to 7 is administered to a patient requiring such a treatment or prevention.
11. A pharmaceutical product comprising at least one compound as claimed in any of claims 1 to 7 and one or more pharmaceutically acceptable carriers and/or excipients.
12. A process for preparing compounds as claimed in any of claims 1 to 7, characterized in that a) an open-chain carbonyl compound of the general formula (II) is cyclized where appropriate with addition of an inorganic or organic acid or Lewis acid to a compound of the general formula (III) b) the compound of the general formula (III) is converted by replacing the hydroxy group by the amino group into a compound of the general formula (IV) IMG>
and c) the compound of the general formula (IV) is converted by reaction with a compound selected from compounds of the general formulae R3-X-Nu (where Nu is a nucleofugic group), R3-N=C=O or R3-N=C=S, and where appropriate subsequent replacement of a carbonyl oxygen atom by sulfur, into a compound of the general formula (I), where the substituents R1 to R12 and X have the meanings indicated in claims 1 to 7.
and c) the compound of the general formula (IV) is converted by reaction with a compound selected from compounds of the general formulae R3-X-Nu (where Nu is a nucleofugic group), R3-N=C=O or R3-N=C=S, and where appropriate subsequent replacement of a carbonyl oxygen atom by sulfur, into a compound of the general formula (I), where the substituents R1 to R12 and X have the meanings indicated in claims 1 to 7.
13. A process for preparing compounds as claimed in any of claims 1 to 7, characterized in that a compound of the general formula (IV) as described in claim 12 is reacted with a compound of the general formula R3- (CH2),-CHO (where v is 0, 1 or 2), and the resulting imine is hydrogenated to give a compound of the general formula (I), where X has the meaning -(CH2 ) p- indicated in claim 1, and the substituents R1 to R12 have the meanings indicated in claims 1 to 7.
14. A process for preparing compounds according to any of claims 1 to 7, characterized in that a compound of the general formula (IV) as described in claim 12 is reacted with phosgene or thiophosgene, and the resulting isocyanate or isothiocyanate is subsequently reacted with compounds of the general formula R3-OH or R3-NH2 to give a compound of the general formula (I), where X has the meaning -C(=O)-NH-, -C(=S)-NH- or -C(=O)-O- indicated in claim 1, and the substituents R' to R12 have the meanings indicated in claims 1 to 7.
15. A process for preparing a compound as claimed in any of claims 1 to 7, characterized in that a) a compound of the general formula (VI) where R 8 is a (C1-C10) -alkyl group, is reacted with an a-keto carboxylic acid or an a-keto carboxylic ester of the general formula R5-C(=O)-COOR13 in an ene reaction in the presence of an optionally chiral Lewis acid to give a compound of the general formula (VII) in which R7 and R8 together have the meaning of a (C1-C10)-alkylidene group, b) the compound of the general formula (VII) is reduced to an aldehyde of the general formula (IIa), in which R7 and R8 together have the meaning of a (C1-C10) -alkylidene group, and c) the aldehyde (IIa) is converted in analogy to the process indicated in claim 12 into a compound of the general formula (I) in which R7 and R8 together have the meaning of a (C1-C10) -alkylidene group, where the substituents R1 to R13 have the meanings indicated in claims 1 to 7.
16. The use of compounds of the general formula (IV) where the substituents R1 to R12 have the meanings indicated in claims 1 to 7, for preparing compounds of the general formula (I) as claimed in any of claims 1 to 7.
17. A compound of the formula (IV), where the substituents R1 to R12 have the meanings indicated in claims 1 to 7.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102005017326.8 | 2005-04-14 | ||
DE102005017326A DE102005017326A1 (en) | 2005-04-14 | 2005-04-14 | Tetrahydronaphthalene derivatives, process for their preparation and their use as anti-inflammatory agents |
PCT/EP2006/003781 WO2006108712A1 (en) | 2005-04-14 | 2006-04-13 | Tetrahydronaphthalene derivatives method for the production and the use thereof in the form of antiphlogistics |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2598208A1 true CA2598208A1 (en) | 2006-10-19 |
Family
ID=36608763
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002598208A Abandoned CA2598208A1 (en) | 2005-04-14 | 2006-04-13 | Tetrahydronaphthalene derivatives, processes for their preparation and their use as antiinflammatory agents |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1868986A1 (en) |
JP (1) | JP2008535890A (en) |
CN (1) | CN101146765A (en) |
CA (1) | CA2598208A1 (en) |
DE (1) | DE102005017326A1 (en) |
WO (1) | WO2006108712A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1958934A1 (en) * | 2007-02-16 | 2008-08-20 | Bayer Schering Pharma Aktiengesellschaft | Tetrahydronaphthalenylamides, a process for their production and their use as anti-inflammatory agents |
CA2769563A1 (en) | 2009-07-31 | 2011-02-10 | Cadila Healthcare Limited | Novel compounds as modulators of glucocorticoid receptors |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2665443B1 (en) * | 1990-08-03 | 1992-11-06 | Lucien Laboratoires | DERIVATIVES OF AMINO-4-METHYL-1-TETRALINES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION. |
DE19723722A1 (en) * | 1997-05-30 | 1998-12-10 | Schering Ag | Nonsteroidal progestogens |
DE10038639A1 (en) * | 2000-07-28 | 2002-02-21 | Schering Ag | New and known N-aryl 2-hydroxy-omega-arylalkanamide derivatives, useful e.g. for treating inflammatory diseases such as rheumatism |
-
2005
- 2005-04-14 DE DE102005017326A patent/DE102005017326A1/en not_active Ceased
-
2006
- 2006-04-13 CA CA002598208A patent/CA2598208A1/en not_active Abandoned
- 2006-04-13 CN CNA2006800092011A patent/CN101146765A/en active Pending
- 2006-04-13 WO PCT/EP2006/003781 patent/WO2006108712A1/en not_active Application Discontinuation
- 2006-04-13 EP EP06742671A patent/EP1868986A1/en not_active Withdrawn
- 2006-04-13 JP JP2008505846A patent/JP2008535890A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
DE102005017326A1 (en) | 2007-03-29 |
JP2008535890A (en) | 2008-09-04 |
WO2006108712A1 (en) | 2006-10-19 |
CN101146765A (en) | 2008-03-19 |
EP1868986A1 (en) | 2007-12-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20070129359A1 (en) | Tetrahydronaphthalene derivatives, processes for their preparation and their use as antiinflammatory agents | |
US7109212B2 (en) | Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors | |
KR100967277B1 (en) | Quinoline and isoquinoline derivatives, method for the production thereof and use thereof as anti-inflammatory agents | |
CA2586973A1 (en) | Tricyclic amino alcohols, processes for synthesis of same and use of same as anti-inflammatory drugs | |
JP2008529963A (en) | Heterocyclic-substituted pentanol derivatives, methods for their production and their use as anti-inflammatory agents | |
US7442794B2 (en) | Rearranged pentanols, a process for their production and their use as anti-inflammatory agents | |
US20070015750A1 (en) | Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents | |
US20070015761A1 (en) | Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents | |
US8097627B2 (en) | Multiply-substituted tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents | |
WO2008006627A1 (en) | Benzyl amines, a process for their production and their use as anti-inflammatory agents | |
US20070225290A1 (en) | Tetrahydronaphthalene derivates, processes for preparing them and their use as antiinflammatory agents | |
US20050090559A1 (en) | Heterocyclically-substituted pentanol derivatives, process for their production and their use as anti-inflammatory agents | |
JP2008512416A (en) | Alkylidene-tetrahydronaphthalene derivatives, their preparation and use as anti-inflammatory agents | |
US20060167025A1 (en) | Tricyclic amino alcohols, processes for synthesis of same and use of same as anti-inflammatory drugs | |
US20060084652A1 (en) | Alkylidene-tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents | |
US20080188666A1 (en) | Linear phenyl-substituted indazoles and indoles, a process for their production and their use as anti-inflammatory agents | |
US20050222154A1 (en) | Multiply-substituted tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents | |
CA2598208A1 (en) | Tetrahydronaphthalene derivatives, processes for their preparation and their use as antiinflammatory agents | |
US20050267202A1 (en) | Chromanol derivatives, a process for their production and their use as anti-inflammatory agents | |
US20060247292A1 (en) | Benzocycloheptene derivatives, process for their production and their use as anti-inflammatory agents | |
US20070129358A1 (en) | Sbstituted chroman derivatives, processes for their preparation and their use as antiinflammatory agents | |
WO2008055709A1 (en) | Indazole and indole derivatives as anti -inflammatory agents | |
DE102005018025A1 (en) | New heterocyclic compounds which are cytokine interleukin-8 inhibitors useful for treating e.g., chronic obstructive lung disease, bronchitis, rheumatoid arthritis, psoriasis, gastrointestinal disease and Crohn's disease | |
CA2598969A1 (en) | 6, 7, 8, 9-tetrahydro-5-amino-5h-benzocyclohepten-6-ol derivatives and related compounds used as anti-inflammatory agents | |
CA2598207A1 (en) | Substituted chroman derivatives, method for the production and the use thereof in the form of antiphlogistics |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |